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Reports in the literature have shown that in man pro-
pranolol has a larger first-pass effect (70%) than pindolol 
(13%). The aim of this research was to make a direct com-
parison of first-pass extraction and other pharmacokinetic 
parameters of these drugs under identical experimental con-
ditions by means of an isolated rat liver perfusion model. 
Livers were removed from Long-Evans rats and these were 
perfused with a recirculating perfusate medium of 20% rat 
blood - BO% KREBS buffer. Pressure was held constant at a 
physiologically acceptable level of 16 cm of water so that, 
iii 
as in the in vivo situation, each liver determined its own 
individual flow rate. 5 mg of either propranolol or pindolol 
were injected as a single bolus into the reservoir (simulating 
intravenous administration) and samples taken at 1, 3, 5, 10, 
20, 30, 40 and 60 minutes from the portal venous inflow into 
the liver and the hepatic venous outflow from the liver. 
Whole blood-KREBS concentrations for both propranolol 
and pindolol were obtained by spectrofluorometric assays. 
Logarithmic drug concentrations were plotted against time and 
the best lines fitted. Points were then derived and transposed 
on to linear graph paper so as to calculate the areas under 
the drug concentration-versus-time curves. 
Propranolol and pindolol differed in the following 
respects: 
(i) The first-pass effect (hepatic extraction ratio) of 
propranolol (0,71) and its hepatic clearance (2,47 ml/g/min) 
were highly significantly greater than the corresponding 
values (0,50 and 1,56 ml/g/min respectively) for pindolol 
(p<O,Ol) even when perfusions were strictly controlled for 
flow. 
(ii) The hepatic intrinsic clearance of propranolol (10,44 
ml/g/min) was very highly significantly greater than that of 
pindolol (3,42 ml/g/min) (p(0,001). 
(iii) The correlation between perfusate flow rate and ex-
traction ratio was significant in the case of the pindolol 
perfusions (r = -0,88; p<0,01) but not in the propranolol 
group (r = -0,74; p<0,10). 
(iv) Significant correlations were obtained between flow 
rate and hepatic clearance in both the propranolol (r = 0,97; 
p<0,001) and the pindolol (r = 0,87; p<0,05) groups of per-
fusions. 
(v) The portal venous logarithmic concentration-time 
iv 
graphs conformed to a biexponential two-compartment system in 
the case of propranolol but a monoexponential one-compartment 
model in the case of pindolol. 
(vi) The ~-phase ti of propranolol was rapid ( tt o4 = 1 minute) 
and flow-dependent whereas the ti~ was relatively slow 
(tti = 5,1 minutes) and non-flow-dependent. Its t 1} was longer 
than that for pindolol (t!J = 4 minutes), the latter being 
flow-dependent. 
(vii) The apparent volume of distribution of propranolol 
(21,23 ml/g) was larger than that for pindolol (8,72 ml/g) 
(p<0,001). 
These results supported the "venous-equilibration" model 
of hepatic clearance. The pharmacokinetic characteristics of 
propranolol identified it as a high clearance, flow-limited 
drug whereas pindolol emerged as an intermediate, partly flow-
limited drug. 
It was proposed that the higher first-pass extraction of 
propranolol was predominantly the result of avid, high affinity 
binding to liver sites. It was the extent of this binding 
which created a two-compartment system for propranolol - with 
the exceedingly high extraction ratio in the o(.-phase (0~99 
after 1 minute of perfusion) - and accounted for the much 
larger apparent volume of distribution of propranolol. 
The differences in the pharmacokinetics of the two beta-
blockers may be related to the higher lipid-solubility and 
resultant greater tissue penetrability of propranolol. ·The 
larger first-pass extraction and hepatic intrinsic clearance 
of propranolol compared to those of pindolol may reflect 
not drug metabolism per se but rather the hepatic uptake of 





Pindolol ( 1 Visken 1 , Sandoz) is a potent ~-receptor 
antagonist or i-blocker. Its indole nucleus, unique among 
J-blockers, is the only feature that differentiates it from 
propranolol (1nderal! I.C.I.) which has a naphthalene ring 
structure (Fig. 1). This relatively small modification in 
aromatic ring structure between the two compounds accounts 




Fig. 1. Struc~ures of Pindolol and Propranolol 
i-blockers are used extensively in the treatment of 
hypertension, angina pectoris and cardiac arrythmias (12, 37, 
55, 69). Pindolol is at least five to ten times more potent 
than propranolol on a weight-to-weight basis and, unlike 
propranolol, it possesses intrinsic agonist activity (21, 47, 
48, 96). 
1. 
All ~-adrenoreceptor blocking agents can be characterised 
as weak bases. In the acidic or slightly alkaline gastro-
intestinal fluid, they exist predominantly in an ionised, 
easily soluble form because of the secondary amino group in 
the side-chain which has a pk value of 9,5 - 9,7. They are a 
rapidly and well absorbed from the gastro-intestinal tract 
and peak blood concentrations are reached one to two hou r s 
after ingestion (12, 37, 55). 
However, it is now well established that the important 
factor is not the absolute amount of drug absorbed but rather 
the amount which becomes systemically available thereafter. 
In its passage from the gut to the systemic circulation the 
drug traverses the liver~ the portal system. It is in the 
liver that some of the drug is extracted and metabolised. 
2. 
This extraction occurs during the drug's first passage through 
the liver and before it enters the circulation for general 
distribution (Fig. 2). This phenomenon is referred to as 
first-pass metabolism, first-pass extraction or the first-pass 
effect. 
. . . . . 
. . ..... . . 
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Fig. 2. "First-pass extractionµ. A diagrammatic represent-
ation of oral and intravenous administration. The shading re-
presents drug concentration and the arrows represent route of 
administration. Since the major organ of elimination is the 
liver, the drug can be extracted from portal venous blood 
prior to reaching the systemic circulation during oral ad-
ministration (after Nies, A.S. and Shand, D.G. (69)). 
A large first-pass extraction would result in a low 
systemic bioavailability of the drug after oral administration 
despite complete absorption. The lower bioavailability of a 
drug with a high first-pass extraction can be partly com-
pensated for by administering a higher dosage. However, a 
large genetically determined inter-individual variation in 
first-pass extraction can create wide differences in ·plasma 
levels of the drug, even in patients receiving identical 
doses, particularly when the first-pass extraction is large. 
In general, many other factors may also affect the 
3. 
first-pass extraction and hence bioavailability of a drug. 
These will be discussed in a later section. 
Several groups of workers (3, 21, 56) had found that 
pindolol had a first-pass effect in man that was apparently 
much lower than that established for propranolol (18, 31, 
46, 50). 
This project was set up to test whether propranolol 
differed in its first-pass effect from that of pindolol in 
an isolated rat liver perfusi?n model. There are no data 
available which make a direct comparison of the first-pass 
effect of these two drugs using identical experimental con-
ditions. 
1.2. Review of the Literature 
1.2.1. General Introduction to Pharmacokinetics 
In this project several pharmacokinetic parameters are 
derived in order to study the differences between pindolol 
and propranolol. In view of the fact that pharmacokinetics 
are a complex and mathematical field, the introduction that 
follows is confined only to those aspects which bear directly 
on the subject of my research. 
All the abbreviations used in the following chapters 
are shown in Appendix B. 
1.2.2. First-order Elimination Kinetics 
In first-order elimination kinetics the rate of elimi-
nation is proportional to the amount of drug in the body (DB) 






= k el DB 
cit 
= overall first-order elimination rate constant 
which has the dimensions of time· (If the 
drug is eliminated only by the liver then kel 
represents the hepatic rate constant.) 
A plot of the logarithm of concentration-versus-time is 
linear in first-order kinetics. 
1.2.3. Elimination Half-life (t~l 
This is the time required for the plasma concentration 
of drug to fall by 50%. 
(for first-order kinetics) 
(equation 1) 
where kel = fir s t-order elimination constant. 
1.2.4. Apparent Volume of Distribution (Vdl 
Once a drug has been absorbed and reaches the systemic 
circulation, it distributes into organs and tissues. The 
apparent volume of distribution is that volume in which the 
drug would appear to be distributed during the steady state 
4. 
if it existed throughout that volume at the same concentration 
as in the plasma. 
For drugs which are eliminated by first-order processes, 
the volume of distribution is calculated as follows: 
= (equation 2) 
where D = dose 
and c = theoretical plasma concentration at zero time 
0 
when distribution is complete. 
1.2.5. Compartmental Drug Disposition 
Pharmacokinetics are most frequently explained by the 
one-compartment and two-compartment open models. In the one-
compartment model, drug entering the body is distributed in-
stantaneously into the available space and is eliminated 
directly from t his single pool of drug. Assuming first-order 
kinetics plasma concentrations-versus-time plotted on a semi-
logarithmic scale depicts a straight line (Fig. 3). 
An open two-compartment model is needed to explain the 
pharmacokinetics of most drugs. Drug entering the body in-
stantaneously distributes into a space, termed the central 
compartment, which consists of blood and other readily access-
ible fluids and tissues {e.g. liver and lung). Drug distri-
bution is much slower into a second compartment (the peripheral 
compartment) which consists of poorly perfused organs and 
tissues (e.g. adipose and muscle). Elimination occurs from 
the central compartment. Plasma concentration-versus-time 
plotted on a semi-logarithmic scale produces a curve which 
can be broken down into two exponential components. 
~~-D-
• t 
Fig. 3. Pharmacokinetic models. Accompanying 
semi-logarithmic plots of plasma concentration- (C) 
versus-time (t) are consistent with an open one-
compartment (above) and two-compartment model 
(below) (after Gibaldi, M. (86)). 
The °'-phase represents the distribution phase and re-
' fleets primarily distribution from the central to the peri-
5. 
pheral compartment although elimination begins from the first 
moment when drug is injected. When distribution is complete 
and equilibrium reached, the two lines meet and thereafter 
elimination dominates. However, although the~ component 
reflects elimination kinetics it also reflects distribution 
from the peripheral to the central compartment (Fig. 3) (134). 
Multicompartment models produce curves that can be 
broken down into more than two components 
1.3. The Kinetics of Hepatic Elimination 
1.3.1. Hepatic Extraction Ratio (E) 
The hepatic extraction ratio (E) can be estimated from 
the arterial-venous concentration difference across the liver 
at steady state. However, after a single dose of drug is ad-
ministered, a constant extraction ratio is only achieved once 
distribution equilibrium is complete. A valid estimation of 
the extraction ratio can nevertheless be obtained using the 
areas under the inflow and outflow concentration-ve~sus-time 
curves. 
Thus 
E = AUCPV - AUCHV 
AUCPV 
This corre~ponds to 





where AUCPV = area under the portal vein concentration-
versus-time curve= area under the systemic con-
centration-versus-time curve after intravenous 
administration. (This represents inflow into 
the liver.) 
AUCHV = area under the hepatic vein concentration-
versus-time curve. (This represents outflow 
from the liver.) 
The hepatic extraction ratio of a single dose of intra-
venously administered drug is equivalent to the extraction 
of the drug during its first pass through the liver after 
oral administration (46, 94). Thus the extraction ratio de-
rived from equation 3 is equal to the first-pass extraction. 
1.3.2. Hepatic Clearance of Total Drug (ClH) 
The efficiency of any organ in removing a drug irreversibly 
from the perfusing blood is describad by the term clearance. 
Hepatic clearance (ClH) is the volume of blood from which drug 
is completely removed in unit time. It can be calculated from 
the product of the hepatic blood flow and the hepatic extrac~ion 
ratio (i.e. the difference in the arterial-venous concentration 
across the liver at steady state). 
ClH • Q [cs cs cv] • Q E (equation 4) 
where Q = total hepatic blood flow 
C = mixed portal venous and arterial 
s 
concentration of total drug= 
systemic concentration of total 
drug 
C = hepatic venous concentration of 
V 
total drug 
E = steady state extraction ratio 
Hepatic clearance can also be calculated according to 
the following equatioris if extrahepatic elimination is 
negligible and elimination is first-order: 
ClH = 




where vd = 
ti = 
Q E = D. 1V 
ALIC (equation 5) s 
intravenous dose of drug 
area under the drug concentration 
time curve in the systemic blood. 
(equation 6) 
apparent volume of distribution 
elimination half-life. 
1.3.3. Bioavailability (f) 
The fraction of drug which escapes hepatic extraction 
or first-pass extraction is an index of the bioavailability 













1 E (equation 7) 
AUCHV 
s (equation 3) 
ALIC 




(after administration of a single intravenous 
dose) 
1.3.4. first-pass Extraction - a Compartmental Model 
7. 
Ordinary compartmental pharmacokinetics are not sufficient 
to predict the pharmacokinetics of drugs subject to first-
pass extraction. Gibaldi has thus proposed a new approach 
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Fig. 4. First-pass pharmacokinetic model, 
a three-compartment open model (after 
Gibaldi, M. et al (27)). 
8. 
In this model elimination occurs from a compartment 
which is distinct from that containing the vascular sampling 
site. Hence, although the plasma concentration - time data 
simply suggest a two-compartment model as described in 
section 1.2.5., an additional rapidly accessible camp~rtment 
is proposed. This compartment from which elimination occurs 
is analogous ta the hepato-portal system. Drug introduced 
into the portal vein (oral administration) will go directly 
into this compartment. Using this model, Gibaldi has derived 
a number of equations ta calculate drug clearance and bia-
availability. 
f can be calculated from drug concentration - time data 
obtained after intravenous administration of a drug (27, 77, 
94, 95). 
where 
f = 1 
o. 
l. V 








(from equation 5) 
The above equation indicates that oral bioavailability 
can be ctt?ulated even after intravenous administration and 
thus Q • ~tc is equal ta the first-pass extraction of a 
5 
drug if elimination occurs only from the hepato-portal system. 
9 • 
1.4. Models of Hepatic Drug Clearance 
Two models have been put forward to explain and predict 
drug clearance. Although the two models have different 
assumptions, in practice the differences in hepatic clearance 
and extraction that each predictsare not very large. Moreover, 
the broad principles involved in hepatic clearance are not 
critically dependent on the model chosen (131). 
One of the models is the "parallel tube" model. This 
' 
involves complex pharmacokinetics and enzyme kinetics. It 
is discussed in detail by Brauer (119) and Keiding et al (99). 
The most commonly used model and the one relevant to 
this thesis is the "venous-equilibration" model (also known 
as the perfusion limited model and the "well-stirred" model) 
(18, 19, 20, 85). 
1.5. The "Venous-eguilibration" Model of Hepatic Drug 
Clearance 
From equation 4, hepatic drug clearance depends on two 
biological variables: (i) hepatic blood flow, and (ii) the 
extraction ratio which must reflect the intrinsic ability of 
the liver to metabolise drug. Hepatic drug clearance also 
depends on a third variable, the binding of drug to plasma 
proteins and cellular components of blood. 
Blood and plasma concentration/time profiles are fre-
quently used to characterise drug kinetics and are usually 
interpreted by compartmental analysis. However, these 
analyses do not indicate the relationship between the three 
biological variables mentioned above. The "venous-equi-
libration" model of hepatic elimination incorporates the bio-
logical variables mentioned and thus further clarifies drug 
elimination and disposition. It is based on the model of 
Rowland et al (20), Branch et al (19) and Gillette (85). 
One of the critical assumptions of the model is that 
drug distributes so rapidly as it passes through the liver 
that drug concentration within the liver is in equilibrium 
with that in the emergent venous blood. Other assumptions 
are: (i) elimination is first-order, (ii) absorption is com-
plete, (iii) all or most of the drug is eliminated by the 
liver (50), and (iv) that the volume of distribution does 
not change ( 125). 
The equations and inter-relationships predicted by the 
model are described in the following sections and are found 
in the following references (17, 18, 19, 22, 24, 25, 32). 
1.5.1. Intrinsic Clearance of Total Drug (Clint) 
10. 
The extract i on ratio depends on both liver blood flow 
and on the overall inherent ability of the liver to extract 
and metabolise the drug by rate-limiting processes. The term 
intrinsic clearance of total drug (Clint) has been introduced 
to describe this ability of the liver and it is independent 
of any modifying effects of flow. Thus intrinsic clearance 
is defined as "the maximal ability of the liver to irreversibly 
remove drug from the blood by all pathways in the absence of 
any flow limitations"{17). 
In effect, then, intrinsic clearance is a composite of 
several different processes: (i) the partitioning of the 
drug from the blood into the liver, (ii) liver size,and (iii) 
the intrinsic overall rate ·of elimination by biochemical 
processes, i.e. Vmax (l) when metabolism is first-order and 
-r;-
flow is not rate-limiting. 
Intrinsic clearance is a distinctive characteristic for 
any particular drug at a given dose in a given situation. 
1.5.2. Relationshi between He Intrinsic 
c earance 1 xtraction ratio and low rate 
If it is assumed that drug binding to blood constituents 
remains constant and that there is no extrahepatic clearance 
(i.e. hepatic clearance ClH = systemic clearance Cls) the 
following relationship can be derived after single dose intra-
venous administration• 
ClH = Clint • AUCHV AUCS {equation 9) 
Now ClH = Q E {equation 4) 
(1) V = maximum rate of the reaction (metabolism) max 
k = Michaelis-Menton constant m 
11. 
and ALICHV = f = 1 
ALIC 
E (equations 7 and 8) 
s 
. 
Clint (1 - E) Q E = • • 
• E Clint = • • Q + Cl. t in (equation 10) 
• 
[ Cl. t ~ • • Q E = Q Q + ~~int (equation 11) 
• 
• • = Q E Clint 
1 - E (equation 12) 
1.5.3. Calculation of Intrinsic Clearance from chan es in 
low and Extraction ratio 
line 
Equation 11 can be rearranged to give: 
1 
T = 1 
Thus plot l a of-E 
with an intercept 
Q 
+ Cl. t in 
against Q 
of one and 
(equation 13) 
should yield a straight 
1 
a slope of Cl. 
int 
1.5.4. Calculation of Intrinsic Clearance after Intravenous 
administration of Drug 
If extrahepatic clearance is negligible, then equation 5 


















Thus Cl. t can be calculated from the intravenous dose ad-in 
ministered divided by the area-under-the-concentration-time-
curve in the hepatic vein. ALICHV will therefore be independent 
of flow. 
12. 
1.5.5. Calculation of Intrinsic Clearance after Oral admini-
stration of Drug 
A formula for intrinsic clearance has been derived after 
oral administration of the drug if absorption is complete and 
there is no extrahepatic clearance. 
where D 
0 
Cl. t = D 
. in o 
ATic 
0 





in the systemic circulation after oral 
administration. 
Interestingly enough, this relationship indicates that 
AUC is independent of flow and depends only on the dose and 
0 
Cl. t' regardless of whether the drug has a low or high clearance in 
(assuming absorption is complete and there is no extrahepatic 
clearance). The AUCHV after intravenous administration 
will be equal to ALIC in the systemic circulation after oral 
administration of the same dose. 







1.5.6. The effect of changes in flow on hepatic drug clearance 
The relationship between hepatic drug clearance and flow 
according to the "venous-equilibration" model is described by 
equation 11. 
= Q E = 
Fig. 5 shows the relationship between flow and actual 
clearance (as distinct from intrinsic clearance); the latter 
is calculated from the product of liver blood flow and ex-
traction ratio. It will be seen (at the extreme right of the 
curve) that when flow is infinitely large, the actual clearance 
approaches the intrinsic clearance (i.e. its maximum possible 
clearance) and flow does not therefore affect clearance sub-
stantially. However, where flow is small compared to intrinsic 
clearance (Clint), as in the extreme left portion of the curve, 
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Fig. 5. Theoretical relationship between liver blood 
flow and actual drug clearance. Both flow and actual 
clearance have been calculated as multiples of in-
trinsic hepatic clearance using equation 12 in the 
text (after Branch et al (19)). 
13. 
in flow. In the intermediate portion of the curve the effect 
of flow on actual clearance is less marked. 
Because in vivo liver blood flow is not infinitely 
variable, only a portion of the curve in Fig. 5. will be 
applicable for a drug depending on the Cl. t characteristic 1n 
for that particular drug. 
When Clint 
equation 10 (E 
is equal to liver blood flow according to 
= Clint ), the extraction ratio is 0,5. 
Q + Cl. t 1n 
With intrinsic clearances lower than blood flow the extraction 
is less than 0,5; at intrinsic clearances higher than blood 
flow hepatic extraction exceeds 0,5. 
Fig. 6 shows the set of curves representing the actual 
clearance versus liver blood flow for drugs which have different 
intrinsic clearances corresponding to extraction ratios from 
0,1 to D,9 at normal liver blood flow. Clearly for drugs with 
low Cl. t values and low E(<D,5) actual clearances are independ-1n 
ent of blood flow, while the clearances of drugs with high 
Cl. t value and high E{)D,5) are flow dependent. 1n 
Fig. 7 demonstrates the relationship between liver blood 
flow and extraction ratio (E). It is apparent that where 
drugs have high extraction ratios increasing the blood flow 
produces minimal decrease s in E; where drugs have a low 
extraction ra tio increasing the blood flow results in sub~ 
stantial decreases in E • 
• 
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Fig. 6. The relationship between liver 
blood flow and hepatic clearance for drugs 
with varying extraction ratios (ER). The 
arrows indicate the range over which liver 
blood flow can vary and extraction ratios 
refer to a normal flow of 1,5 1/min (after 
Wilkinson and Shand: Clin, .Pharm. Ther. 
1§., 377-390, 1975 (25)). 
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Fig. 7. The relationship between liver 
blood flow and hepatic extraction ratio for 
drugs with varying extraction ratios. The 
individual curves reflect a 10% stepwise 
change in extraction at a normal flow of 
1,5 1/min and therefore each is comple-
mentary to the equivalent curve in Fig. 6. 
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The reason that very low intrinsic clearance (very low E) 
drugs have actual clearances that are independent of flow (as 
shown in Fig. 6) is that with these drugs an increase in blood 
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flow results in a nearly equal decrease in E so that the 
product of flow and E (i.e. actual clearance) remains re-
latively unchanged. With very high intrinsic clearance 
(very high E) drugs an increase in flow produces a minimal 
decrease in E and thus the ~ctual clearance (i.e. flow x E) 
is definitely increased. With intermediate intrinsic 
clearance drugs, the effects of flow on E and thus on actual 
clearance are a l so intermediate. 
1.5.7. The effect of changes in intrinsic clearance on 
hepatic drug clearance 
As discussed in section 1.5.1., Cl. tis inter alia 1n 
dependent on hepatic enzyme activity. Thus changes in 
hepatic metabolism can result in changes in Cl. t which in 1n 
turn can affect actual drug clearance. 
Changes in Cl. twill have the most marked effect on 1n 
actual clearance in the case of drugs which have small 
Clint values. For example, an increase in Clint from 
167 ml/min to 357 ml/min will produce an increase in E from 
D,l to 0,2 at a liver blood flow of 1,5 litres/min in humans 
(E = Clint ) and thus double the actual clearance 
Cl. t + Q 1n 
(flow x E)(24). 
On the other hand changes in Cl. twill not have a 1n 
noticeable effect on actual clearance in the case of drugs with 
high Cl. t values. Thus an increase in Cl. t from 6 litres/min 1n 1n 
to 13,5 litres/min will increase E from O,B to 0,9 and thereby 
increase clearance by only 12,5%. 
1.5.B. The effect of changes in drug binding on hepatic drug 
clearance 
There is one other variable that must be considered when 
assessing drug clearance. Binding to plasma proteins and/or 
other blood constituents is an important determinant of drug 
disposition. If the availability of the drug to the metabolic 
site is limited to the unbound fraction of the drug, then 
binding to plasma proteins or other blood constituents could 
retard metabolism. This is certainly so for drugs with low 
Cl. t and low extraction ratios where the extraction ratio of 1n 
a drug is slightly less than or equal to the unbound fraction 
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of drug (f 8):clearance is then termed restrictive. If the 
Eis very much less than f 8 then binding is not restrictive 
(i.e. restr icted to the free fraction of drug). Since the 
extraction rat io of some drugs is in fact greater than the 
free fraction of drug, elimination in these cases is obviously 
not restricte d to t hat free fraction which is delivered to the 
liver: this elimination is termed non-restrictive. 
It woul d appear in the latter case that the removal of 
bound drug in the liver leads to dissociation (or stripping) 
of bound drug and some of this fraction is subsequently ex-
tracted. The blood then helps transport the drug to its site 
of elimination. 
The effects of binding on hepatic clearance have been 
incorporated into the "venous-equilibration" model. 
where 
1.5.9. 
= Q E = Q [ f 8 Cl int J 
Q + f 8 Clint J 
= fraction of unbound drug in the blood. 
= intrinsic clearance of free drug. This 
is a measure of the inherent ability of 
the liver to clear drug from liver water 
under conditions of first-order meta-
bolism (19). 
= Cl. t (i.e. intrinsic clearance of total in 
drug, free and bound). 
The effect of changes in flow on t~ and bioavailability 
The area under the curve in the systemic circulation after 
oral administration is independent of flow,and Cl. t = 0o in 7m"c" 
(equation 15) - see section 1.5.5. o 
As discussed previously (section 1.5.6.), drugs with small 
Clint values (small E) have systemic clearances that are in-
dependent of flow. Thus half-life and the shape of the areas 
under the curve after oral and intravenous administration are 
unchanged over a wide range of flow rates. 
However, the systemic clearance of a highly extract~d 
drug is definitely flow dependent (section 1.5.6.), 
as is its half-life. As flow increases, half-life decreases 
due to an increased hepatic clearance. Thus the area-under-
the-curve in the systemic circulation 
ministration will be decreased, ClH = 
after intravenous ad-
Div (equation 5) , 
ATic 
s 
However, as flow increases, the extraction ratio decreases 
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to a certain extent so that bioavailability after oral admini-
stration is increased and peak concentrations are higher. 
This increase in bioavailability is offset by the decrease in 
half-life so that ALIC after oral administration remains un-
o 
changed (as expected from equation 15) although the shape of 
the curve will vary with different flow rates. 
1.5.10. The effect of changes in intrinsic clearance on t~~ 
bioavailability 
If the Cl. t of a drug with a low Cl. t (low E, in in 
is increased twofold (say by enzyme induction) there 





The area-under-the-curve in the systemic circulation after 
oral administration will therefore be halved (Clint=~' 
equation 15) in order for the Cl. t to double. AUCo in 
Even though the change in extraction ratio (0,1 to 0,2) is 
large, the effect on bioavailability (f = 1 - E, equation 7) 
is not very marked, i.e. it decreases only from 0,9 to 0,8. 
Thus the 50% decrease in AUC
0 
(50% increase in Clint) must be 
due to the increased drug clearance and thus reduced half-life. 
If, on the other hand, Clint is large (E = 0,9), then 
doubling the Clint will increase Eby only a small fraction 
(say D,9 to 0,95). However, although this first-pass ex~ 
traction after oral administration is increased only a little, 
the bioavailability (1 - E) is greatly decreased (from· O,l to 
D,05). The reduction in the area-under-the-curve (due to the 
increase in Clint) is thus caused by the decreased fraction 
of drug reaching the circulation. The actual clearance and 
thus t, will not be affected by the change in Clint· 
1.5.11. Validation of the "Venous-Equilibration" Model 
The validity of the theoretical conclusions reached by 
the "venous-equilibration" model has been established by Shand 
et al using an isolated rat liver perfusion model shown in 
Fig. 8 (17). 
Fig. 8. Diagram of the perfusion 
circuit. Solid arrows represent 
the two sites of drug administration 
and open arrows the sampling sites 
from the reservoi r and the hepatic 
vein (after Shand et al (17)). 
Rat livers were perfused via the portal vein at a con-
stant flow rate of 20 ml/min with 100 ml of 20% rat blood-
80% KREBS buffer. The reservoir simulated the 'systemic 
circulation' and drug administered directly into the re-
servoir represented intravenous dosing. Drug administered 
into the portal vein simulated oral dosing since the drug 
had to pass through the liver before it could reach the 
reservoir ('systemic circulation'). 5 mg of propranolol 
were injected over 30 seconds either into the reservoir 
or into the portal vein and samples were taken at various 
times over 60 minutes from the reservoir and directly from 
the venous effluent (Fig. 8). 
In another set of experiments the effect of changing 
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the perfusate flow from 20 ml/min to 10 ml/min was examined. 
Using this model Shand et al were able to show the following: 
(i) AUCHV (ALIC in the hepatic vein after intra-
venous dosing) and ALIC (ALIC in the reservoir 0 
after oral dosing) were not significantly 
different. (Clint= Div = 0o ) (section 1.5.5.) 
AUCHV AUC 0 
(ii) AUCHV and AUC 0 were independent of flow 
changes, even though the shape of the curve 
(and the tt) were different at the two flew 
rates (see section 1.5.9.). 
(iii) The extraction ratio calculated as 
E = Clint (equation 10) agreed well 
Cl. t + Q in 
with the value obt~ined by measuring the 
extrac ti on ratio directly. (Eq~ation 3.) 
AUCPV - AUCHV 
AUCPV 
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These principles also held for lidocaine and diphenyl-
hydantoin, drugs which have extraction ratios that are greater 
and smaller than propranolol respectively (17). 
In humans it has been shown that oral drug clearance 
(and hence intrinsic clearance) is not affected by flow (18, 
43) (see equation 15, section 1.5.5.). 
Rane et al used an in vitro measurement of the kinetic 
constants V and k to obtain Cl. t and hence extraction max m in 
ratio. They compared this value with the extraction ratio 
determined directly in the isolated liver perfusion. Allow-
ing for liver weight, blood flow and drug binding they found 
a good correlation between the extraction ratios determined 
in vitro and those obtained from the perfusion model (30). 
There is evidence to support the predicted effects of 
changes in liver blood flaw, intrinsic clearance and drug 
binding on the clearance of propranolol (a high clearance, 
high Cl . t drug). (No data are available in the literature in 
for pindolol.) 
(i) Liver blood flow 
Branch et al examined the effect of varying flow on the 
elimination of propranolol by the perfused rat liver (19). 
The effect of flow was greatest when Cl. twas greater than in 
liver blood flow. Using equation 13, they showed that a plot 
off-" versus Q yielded a straight line with an intercept of 
1 and a slope of Cl~ • 
int 
Nies et al have shown in the monkey that hapatic blood 
flow was the major determinant of 
would be expected for a drug with 
propranolol clearance as 
a high Cl. t (60). Racemate in 
propranolol compared to its dextro isomer (devoid of beta-
blocking activity) resulted in a lower clearance of the drug 
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due to a reduction in hepatoportal flow rate induced by 
beta-adrenergic blockade. 
In human subjects a highly significant positive corre-
lation was observed between hepatic blood flow and the 
clearance of dextro-propranolol (18, 82). 
The clearance of propranolol was reduced in liver 
disease in proportion to the decrease in blood flow (107). 
Phenobarbitone increased the clearance of propranolol 
in the monkey by causing an increased liver blood flow; on 
the other hand, it increased the clearance of antipyrine (a 
low Clint compound) by accelerating hepatic drug metabolism 
(125). 
(ii) Intrinsic clearance 
Vestal et al have studied the effect of chlorpromazine 
on propranolol metabolism (109). Once again the kinetic data 
were exactly as anticipated for a high clearance drug like 
propranolol. Chlorpromazine produced a reduction in intrinsic 
(oral) clearance of propranolol, indicating that propranolol 
metabolism was inhibited. However, this had an insignificant 
effect on systemic clearance but affected the bioavailability 
which increased significantly (p<0,005) from 25% to 32%. 
Another study showed that a decrease in Clint from 5,27 
litres/min to 2,62 litres/min had no significant effect on the 
systemic clearance of propranolol but did increase the bio-
availability (41). 
(iii) Drug binding 
Shand et al have shown that in man, dog and rat the 
clearance of propranolol is not dependent on drug binding, 
i.e. clearance is non-restrictive (18, 43, 51). This is what 
is predicted since propranolol has a high extraction ratio 
which is much greater than the free fraction of drug. However, 
if drug binding becomes excessively high, as in the monkey, 
then clearance becomes restrictive (43). 
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1.5.12. Conclus i ons and Summary of Findings derived from the 
"Venous-Equilibrati on" Model 
The "venous-equilibration" model permits the resolution 
of clearance into thr ee measu r able biological parameters: 
flow rate, intri nsic clearance (extraction ratio) and drug 
binding. From t he pra ctical standpoint, this allows the 
changes in clearance caused by liver disease, drug inter-
actions and genetic factors to be analysed and predicted. 
In clin ical te rms the intrinsic clearance can be 
measured conveniently and without recourse to invasive pro-
cedures by divid in g the dose by the area-under-the-curve in 
the systemic circu l a t ion following a single oral admini-
stration of th e drug (equation 15). The extraction ratio is 
easily calcula ted from the equation Clint (equation 10). 
Q + Cl. t in 
The "venou s - equilibration" model thus allows for the 
classification of a drug in terms of its intrinsic clearance 
and extraction r at io from a single, simple measurement. 
(i) Drugs which have a high extraction ratio (i.e. a 
high Clint value which greatly exceeds liver blood flow) will 
have hepatic clearances which are sensitive to changes in 
hepatic blood f l ow but not sensitive to changes in intrinsic 
clearance (flow-limited d=ugs). With such drugs, the elimi-
nation half-life will thus also be sensitive to changes in 
flow but not s e nsi tive to changes in intrinsic clearance. 
There will be a significant first-pass effect after oral ad-
ministration (in view of the high E). Although changes in 
Clint will have relatively little effect on extraction ratio, 
the bioavailability (1 - E) will be markedly affected by such 
changes. The extraction ratio of such drugs exceeds the free 
fraction of drug in the blood and thus elimination is !22.!l::. 
restrictive. 
(ii) 
Cl. t in 
Drugs which have a low extraction ratio (i.e. a low 
value which is substantially less than liver blood flow) 
will have hepatic clearances which are not sensitive to changes 
in hepatic blood flow but are sensitive to changes in intrinsic 
clearance (capacity-limited drugs). With such drugs, elimi-
nation half-life will be independent of changes in blood flow 
but highly sensitive to the liver's ability to metabolise 
the drug. There will be a small first-pass effect after 
oral administration (because of the low extraction ratio). 
Although changes in Cl. twill have major effects on ex-in 
traction ratio, the bioavailability will be relatively un-
affected by such changes. The extraction ratio of such 
drugs is limited to the free fraction of drug in the blood 
and elimination is thus restrictive. 
(iii) Drugs which have intermediate extraction ratios 
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(0,3 - 0,7) will show a partial sensitivity to all three bio-
logical variables - hepatic blood flow, hepatic metabolic 
activity and binding to blood constituents. Such drugs will 
show a mixed profile of the features of groups (i) and (ii), 
depending on the actual value of the extraction ratio. 
1.6. Literary Review of the Pharmacokinetics of Propranolol 
The pharmacokinetics of propranolol have been extensively 
reviewed (55, 69, 132). 
1.6.1. Absorption 
Propranolol is absorbed to the extent of more than 90% 
in man (12, 132). Peak plasma levels are obtained about 2 
hours after administration; these vary from at least 7-fold 
to 20-fold with levels of between 30 ng/ml and 200 ng/ml (31, 
120). Levels of between 50 and 100 ng/ml are required for 
}-blockade (55). Peak levels vary only 2-fold after intra-
venous administration (31). The attainment of individual 
peak plasma levels can be affected by the rate of gastric 
emptying (115). 
1.6.2. Distribution 
Propranolol has a large apparent volume of distribution 
in man and mean values of between 150 litres and 295 litres 
have been reported (18, 31, 68, 80). These volumes exceed 
the physiological body space and they indicate that proprano-
lol is concentrated in extravascular sites. Propranolol 




distribution ratio in octanol/H2o of 5,39. 
In man, propranolol accumulates in the liver and in 
other organs including the heart, brain and lungs (SO, 136). 
Accumulation in the lungs is marked and is sufficient to 
substantially depress the arterial concentration of the 
drug after intravenous injection (136). 
Similar findings have been made in the rat, dog and 
monkey where propranolol was found in the lungs, brain, liver 
and kidney (52, 83, 106). Propranolol accumulated prefer-
entially in the lungs followed by the brain. Accumulation 
in the heart was 5-fold less than in the lung (52) and the 
accumulation in the liver was also less than in these tissues 
(52, 83). Dollery and Junod have established the presence 
of two binding sites in the rat lung, one a high affinity, 
saturable and temperature-sensitive site, and the other 
without these properties (57). The binding was inhibited by 
desmethylimipramine, nortriptyline and chlorpromazine and 
was enhanced by lidocaine (83). 
Hepatic uptake and binding have been extensively 
studied and these are discussed in section 1.6.6. 
Propranolol is highly bound to plasma proteins in humans 
(83% to 96%) (43, 50, 135) and binding is extensive in rats 
(90%), dogs (96%) and monkeys (98,5%) (43). The binding of 
propranolol to human plasma cannot be accounted for by 
albumin alone and other proteins, e.g.c<.1acid glycoprotein, 
are implicated (43, 135). At low concentrations of proprano-
lol plasma binding is co-operative (135). 
Red blood cells also bind significant quantities of the 
drug (43). Blood/plasma ratios of approximately 0,85 have 
been found in monkey, dog and rat, and in man values between 
0,85 and 1,5 have been reported (75, 76). 
1.6.3. Metabolism 
Propranolol is extensively metabolised in the liver in 
man~ ~at 1 dog and monkey. In humans only 25 /J-9 of a 10 mg 
dose given intravenously were excreted as the parent drug (31). 
In vitro work has shown that propranolol is metabolised by the 
microsomal enzyme system requiring NADPH and oxygen. This 
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requirement is characteristic of mixed function oxidases. 
The metabolic pathways are qualitatively the same in man and 
animal species although there are quantitative differences. 
In 1976 Bo nd characterised the metabolites as being 
about 30% acidic and 70% amphoteric (with only minute amounts 
of basic compounds), and he isolated two of the main metabo-
lites, 4-hydroxy propranolol and propranolol glucuronide (110). 





















fig. 9. Schematic repre8entation of propranolol 
metabolism in man and dog. I, propranolol; 
II, desisopropyl propranolol; III, proposed 
aldehyde; IV, glycol; V, naphthoxylactic acid; 
VI, naphthoxyacetic acid; VII, OH-glycol; 
VIII, 4-hydroxy propranolol; IX, naphthol; 
X, dihydroxynaphthalene; XI, isopropylamine; 
(after Walle and Gaffney: (67)). 
The most well documented pathways of metabolism are 
shown in fig. 9. The four primary pathways involve 
0-dealkylation, side-c hain oxidation, glucuronic acid con-
jugation and ring oxidation. 
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Naphthoxylactic acid accounts for 20% of a single oral 
dose but 40% of a single intravenous dose in man and is an 
important metabolite in the rat, dog and monkey. Propranolol 
glucuronide accounts for 2,5% to 25% of a given dose in man. 
The metabolites II, IV, VII, VIII, IX and X (Fig. 9) are 
usually excreted as glucuronides and ethereal sulphates (132). 
Propranolol has fairly varied pharmacological effec~s 
and it is possible that several of the metabolites contribute 
to these properties (67). 4-hydroxy propranolol is the major 
metabolite and it is also an active one (111). Hayes and 
Cooper (52) and others (87) detected 4-hydroxy propranolol 
only after oral dosing; they proposed that hydroxylation 
occurs only when the concentration of propranolol in the 
portal vein exceeds that necessary to saturate the other 
metabolic pathways. 
The isopropylamine metabolite (XI) has sympathomimetic 
activity and it is speculated that the glycol metabolite (IV) 
may contribute to propranolol's central nervous effects (9, 
114). 
1.6.4. Elimination 
Propranolol is almost entirely eliminated by various 
metabolic systems in the liver (37, 51). The systemic 
clearance after intravenous administration (which is thus 
equal to the hepatic clearance) was about 1 litre/min with 
values varying from 0,6 to 1,5 litres/minute (31, 18, 58, 80). 
The plasma elimination .half-life was between 2 - 3 hours but 
values of 4 hours have been reported (18, 58)w 
The intrinsic clearance (oral clearance) in man varied 
between 1,16 litres/min and 6,06 litres/min with an average 
of 2,71 litres/min (18, 31, 50). This is morB than the 
average liver blood flow in man (approximately 1,5 litres/min) 
and indicates that propranolol is a flow-limited drug with a 
high extraction ratio (18, 82, 107). 
In rats the Clint has been estimated as 10 ml/g/min (30, 
41) from in vitro studies of metabolism although a lower value 
of 25 ml/min (uncorrected for liver weight) has been reported, 
using an isolated livei perfusion model (17). The liver 
blood flow in the rat is only 1,2 ml/g/min and this again 
emphasises that propranolol is a flow-limited drug in this 
species. 
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Shand et al have shown that drug concentrations declined 
bi-exponentially after intravenous dosage in man. The early 
~-phase had a half-life of 10 minutes and the later j-phase 
one of 2,3 hours (31) (see fig. 10). A biphasic curve has 
also been observed in the rat (15). Thus propranolol con-























I MEAN t: I.Q IN•II 
5 -t---~---.------,.----.--------
0 2 4 5 6 
TIME, HOURS 
\ 
fig. 10. Plasma propranolol levels 
after a 10 mg intravenous infusion at 
a rate of 1,03 mg per minute. Each 
point represents the mean and standard 
deviation of the levels determined in 
5 subjects (after Shand et al (31)). 
1.6.5. first-pass extraction 
, 
Since propranolol is a drug with a high Cl. t value, in 
one would expect it to have a high extraction ratio, a large 
first-pass effect and a low bioavailability after oral ad-
ministration. There is abundant evidence in the literature 
to support this. In man, Shand and Rangno have shown that 
after an cral dose of 30 mg or less, only traces of un-
changed propranolol could be detected in the circulation and 
extraction was nearly complete (46). In a patient with 
portacaval anastamosis, where portal blood bypasses the 
liver, a large pr~portion of the drug was systemically avail-
able. This proved that the low bioavailability mentioned 
above was due to the first-pass extraction (46). 
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At doses of 40 mg and above the first-pass effect 
dropped to 0,72, indicating that this effect was saturable. 
Wood et al calculated an average bioavailability of 22% after 
a single dose but 34% after chronic dosage. Similar first-
pass extractions of 0,75 (59) and 0,74 (82) were found after 
propranolol administration for several days. First-pass ex-
tractions, however, varied from 40% to BO% in studies by 
Kornhauser (18) and Shand (31). 
Thus the first-pass extraction of propranolol is con-
siderable and also extremely variable in man. This variation 
may be exaggerated by patient non-compliance, poorly controlled 
studies and insensitive assay procedures (70). 
Animal studies have given similar extraction ratios. In 
studies with mongrel dogs, the extraction ratio was measured 
directly using arterial and portal venous blood concentrations 
and was found to be 0,90 (106). Breckenridge et al, using 
similar methods to measure extraction, found values that 
varied from 0,69 to 0,92 (4, 65). 
In an in vivo experiment with rats~ little or no drug 
appeared in the systemic circulation after intraportal ad-
ministration of doses less than O,B mg/kg. As saturation 
occurred, however, extraction decreased from 97,5% (with a 
dose of 0,625 mg/kg) to 50% (with a dose of 5 mg/kg) (15). 
This was also shown using liver perfusions, where drug only 
appeared in the effluent perfusate when concentrations had 
been increased to 20 ,,.ug/ml. 
The extraction ratio in monkeys averaged 0,49, which is 
slightly lower than i~ other animal species (60). 
1.6.6. Hepa~ic Uptake of Propranolol 
In the previous section the saturability of the hepatic 
extracti~n of propranolol was mentioned. This phenomenon has 
been extensively studied and it is apparent that the kinetics 
of propranolol after oral administration are complex. 
Shand and Rangno found that with doses greater than 
40 mg in man hepatic removal became saturated, after which 
there was an app=oximately 60% increase in bioavailability (46). 
Furthermore, it has been proposed that there is a second 
extraction process (pro bably reflecting metabolism) which 
itself becomes saturated by the increased bioavailability 
(50,70). 
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Evans and Shand postulated that this first avid ex-
traction process depended on the physical binding of the un-
changed drug to sites in the liver (50). 
After perfusing isolated rat livers with propranolol, 
Shand and his colleagues homogenised these livers and assayed 
the amount of unchanged drug therein. There was a liver/ 
effluent concentration ratio of 170 : 1 at low concentrations 
of propranolol (10,Mg/ml), and at high concentrations 
(160,.Ug/ml) the ratio decreased to 9,3 : 1 (15). Anderson 
calculated ratios of 12 : 1 to 36 : 1 after a dosage of about 
11 mg (101). 
Thus the extraction of propranolol during liver per-
fusions was dose-dependent. Drug concentration declined 
mono-exponentially following low doses (1 mg) and bi-exponenti-
ally following higher doses (5 mg and above) (14). 
The accumulation of unchanged drug was not affected by 
enzyme inhibitors. This accumulation of drug reflected binding 
and uptake into the liver and is represented by the o(-phase. 
The )-phase, on the other hand, was sensitive to enzyme in-
hibition and apparently represented drug metabolism. Theo(. 
and 1 phases therefore resulted from different biological 
mechanisms (14, 101). 
Several groups of workers have demonstrated that hepatic 
uptake of propranolol involves two binding sites, one with a 
high affinity and low capacity and the other with low affinity 
and a higher capacity (76, 83, 101). Anderson et al found 
that the high affinity site had a dissociation constant of 
3,.ug/ml and a capacity of soo,.ug/g liver. The low affinity 
site had a dissociation constant of 160,µ.g/ml and a capacity 
of 6500,flg/g liver (101). 
Autoradiography shGwed considerable concentrations of 
propranolol in the periportal zones of the liver, indicating 
that propranolo : was e f ficiently clear6d from the perfusate. 
Within these periportal zones certain areas were more heavily 
labelled with isotope than others, suggesti~g that a 
particular type of cell (as yet unidentified) might be in-
volved in propranolol uptake (101). 
Some workers have attributed the high affinity binding 
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to mitochond;ia (83, 101). Propranolol inhibited oxidative 
phosphorylation and increased the permeability of the inner 
mitochondrial membrane to sodium and potassium ions (127, 112). 
Other investigators have minimised mitochondrial binding 
and claimed that the high affinity areas were confined to 
the microsomal fraction. Schneck et al found during in vitro 
studies that there was a correlation between high affinity 
binding and metabolism in the rat. Binding of propranolol 
actually occurred to cytochrome P450 which might it-
self have represented a high affinity site (73, 83). 
It is probable that binding sites are found in both the 
mitochondrial and microsomal fractions (101). Binding to a 
cytosol protein has been excluded (83). Although the exact 
nature of the binding sites is unclear, it would appear that 
hepatic uptake is primarily a phenomenon of physical binding 
to several sites of different affinities, different capacities 
and different intrahepatic locations. 
1.7. Literary Re~iew of the Pharmacokinetics of Pindolol 
The pharmacokinetics of pindolol in relation to other 
1-blockers have been recently reviewed (37). 
1.7.1. Absorption 
Pindolol absorption in man is fast and essentially com-
plete (92%) in subjects fasted overnight (3, 21, 37). The 
absGrption half-life is 25 minutes in man (12) and peak 
plasma levels (20 ng/ml to 80 ng/ml) were reached after about 
80 minutes (21). Levels varied about 4-fold after oral ad-
ministration. Food intake three hours before oral dosage de-
layed peak concentrations by 30 minutes (49). A plasma level 
of 10 ng/ml is required for 1-blockade. Unlike propranolol 
plasma levels ~ise in proportion to the dose and there are no 
non-linear kinetics (5, 64). 
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1.7.2. Distribution 
The mean apparent volume of distribution in man after 
intravenous and oral administration averaged 136 litres and 
142 litres respectively (21). Pindolol is one of the most 
water soluble j-blockers and has a distribution ratio in 
octanol/H 2o of only 0,12 (1, 12). Its volume of distribution, 
although one of the lowest amongst the ,-blockers, still 
significantly exceeds the physiological body space; this in-
dicates that the drug is concentrated in various tissues. 
There is medium binding to plasma albumin (57%) (21) and 
to other plasma proteins (50%) (56) and the average binding 
to serum is about 40% in humans, rats and dogs (100, 105). 
Workers from the Sandoz laboratories have claimed that 
binding of pindolol to red blood cells is an important deter-
minant of its distribution, although they minimised the 
pharmacokinetic significance of this (100). The fraction of 
pindolol in erythrocytes is 0,52 in humans, 0,51 in rats and 
0,59 in dogs (100). This fraction was decreased in vivo in 
rats when the anthranilic acid metabolite of pindolol dis-
placed pindolol from the red blood cells. Uptake of pindolol 
by red blood cells has also been observed in other studies in 
humans (39, 56). 
1.7.3. Metabolism 
In man large doses of pindolol are required to obtain 
sufficient quantities of metabolites for the elucidation of 
their structure. The drug is more extensively metabolised in 
animal species and this has allowed some delineation of the 
metabolic pathways. 
Four different pathways are recognised in rat, rabbit, 
dog and monkey: (i) side-chain conjugation with glucuronic 
acid, (ii) hydroxylation or oxidation with conjugation of the 
indole ring, (iii) oxidative ring scission, and (iv) side-
chain oxidation and deamination (8). 
Kiechel et al have identified nine metabolites from the 
urine of monkeys, rats, cats and rabbits. A diagram of the 
metabolic pathways is shown in Fig. 11 (8). The metabolites 
isolated from rat urine are circled in the diagram. 
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Fig. 11. Metabolic pathways (a - d) of pindolol in rat, 
monkey, rabbit and dog (after Kiechel ~t al (8)). 
Metabolite VIII is a blue dye which causes a green coloration 
in the urine of rats. 
To date no active metabolites of pindolol have been 
identified in man in whom over 90% of the metabolites are 
glucuronides and sulphates (11). 
In rats, however, certain of the metabolites are active 
and appear to ~e important in mediating the effects of the 
drug on blood pressure and heart rate (13). 
1.7.4. Eliminat~on 
The relative water solubility of pindolol facilitates 
its excretion by the kidneys. In man 40% of an administered 
dose is ex~reted unchanged by the kidneys (3, 11, 21, 56). 
This marked extrahepatic elimination makes the estimation of 
hepatic intrinsic clearance difficult. 
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In dogs only 4% to 7% of a 25 mg oral dose was recovered 
unchanged in the urine so that extrahepatic elimination is 
less in this species (40) as it is also in the rat (13). 
The total clearance of pindolol in man averaged 0,48 
litres/min (21, 55, 56). The plasma elimination half-life 
varied between 3 and 4 hours (12, 21). The half-life is only 
30 minutes in the rat (26). 
Initial studies by Gugler suggested that pindolol obeyed 
a one-compartment open model. However the biphasic nature of 
the semi-logarithmic plots of concentration-versus-time - com-
patible with a two-compartment open model - has since been 
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Fig. 12. Mean and s.e. mean of 
time-concentration curves obtained 
in four subjects following a 3 mg 
intravenous bolus of pindolol at 
zero time (after Jennings et al (39)). 
1.7.5. First-pass extraction 
There is considerable evidence that pindolol and practo-
lol have the lowest first-pass extractions among the 
j-blockers in man. 
Gugler et al calculated bioavailability after oral com-
pared to intravenous administration to be 92% (21). This 
figure has baa~ criticised by Jennings and colleagues on the 
grounds that differant subjacts were used for the oral and 
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intravenous administrations. In their study they obtained a 
bioavailability value of 53% which they regarded as being more 
in accord with the drug's rate of systemic clearance (39). 
However, first-pass extractions of only 13% and 20% have 
been reported in the majority of cases (3, 56, 84). Pindolol 
is a drug with a low Clint' a low first-pass extraction and 
a large bioavailability. 
The first-pass extraction was greater in animals. Two 
beagle dogs were given 25 mg of pindolol intravenously and 
then orally after a washout period of three weeks. Bioavail-
ability was 54,2% and 55,2% respectively, indicating a first-
pass extraction of only 45% (40). Metabolism (and thus ex-
traction) is more extensive in rats than man (8, 13). 
1.8. Factors affecting First-Pass Extraction 
From equation 7, bioavailability (f) is equal to (1 - E). 
Thus factors which affect the extraction ratio inversely 
affect the bioavailability. 
Propranolol 
Propranolol has a high Clint' a large extraction ratio 
and therefore a small bioavailability. Even minor changes in 
extraction ratio will have marked effects on bioavailability 
e.g. a change in E from 0,9 to 0,8 will double bioavailability 
from O,l to 0,2 (see page 17). Thus changes i~ Cl. t (i.e. 
in 
changes in metabolism), although producing small effects , on 
first-pass extraction, can be ~ractically important because 
of their large influences on bioavailability. 
Changes in liver blood flow will cause slight (inverse) 
changes in the extraction ratio of a high Cl. t drug like 
in 
propranolol, but these again will have pronounced effects on 
bioavailability. 
Pindolol 
In humans pindolol has a small Cl. t value, a small in 
first-pass ext~action and a high bioavailability. Even if 
the extraction ratio of this drug is substantially altered by 
changes in Cl. tor flow rate (e.g. if E doubles from O,l to in 
0,2), the bioavailability decreases by only 10% (see page 17). 
This will not be of major practical importance. 
In the various animal species studied the extraction of 
pindolol is more extensive than in man. One would expect 
this higher extraction ratio to be affected by the same 
factors which influence propranolol. 
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A multitude of constitutional and environmental factors, 
the presence of disease, and the coadministration of other 
agents can alter the pharmacokinetics of a drug. The following 
gives a brief outline of the factors which may affect the 
first-pass extraction of propranolol and (where data are 
available) pindolol. 
1.8.1. Genetic factors 
The metabolism of drugs is clearly under genetic con-
trol: monozygotic twins showed much greater similarity in 
their metabolism of drugs than did dizygotic twins (2, 79). 
Genetic factors certainly contribute to the large inter-
individual (up to 20-fold) variation (120) found among normal 
subjects after propranolol administration. 
1.8.2. Food 
The influence of food on bioavailability has been studied 
by various workers with conflicting results. Some workers 
have found no correlation between food and bioavailability 
(70, 75). 
Melander et al found an increased bioavailability of 
propranolol when the drug was administered after a meal (81). 
In one report the severity of side-effects in a patient 
especially after meals was attributed to the increased bio-
availability of the drug (122). 
The mechanism by which food decreases the first-pass 
extraction is not known. McLean found that an increased 
hepatic blood flow during drug absorption decreased first-
pass extraction (123). Drug metabolism may also be affected 
by food. The content of the diet (e.g. charcoal-broiled 
beef, high protein, high carbohydrate) can affect metabolism 
in different ways (53, 102). The fact that Walle et al (68), 
unlike other workers, found only a one- to three-fold vari-
ation in plasma propranol ol after oral administration was 
explained by the rigid dietary control imposed on his sub-
jects (132). The metabolism of drugs is reduced in chroni-
cally malnourished patients (88). 
1.8.3. Age 
The range of bioavailability of propranolol obtained in 
children is similar to that observed in adults (117). 
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Hepatic microsomal metabolism, intrinsic clearance and 
first-pass extraction are reduced in the elderly (5) who show 
higher plasma levels of propranolol than do young adults after 
single (130) and continued oral doses (90). 
1.8.4. Drug Interactions 
Halofenate caused a lowering of propranolol levels in 
four subjects on chronic therapy (129), probably by increasing 
the intrinsic clearance and first-pass extraction of proprano-
lol. 
Chlorpromazine resulted in a reduced intrinsic clearance 
of propranolol (4,3 litres/minute to 2,90 litres/minute) and 
an increased bioavailability (25% to 32%) (109). It appears 
from studies in dogs that chlorpromazine altered the metabolic 
pathway of · propranolol (38). 
Several tricyclic antidepressants inhibited propranolol 
metabolism in vitro in the rat (28). Drugs such as amitripty-
line, nortriptyline and chlorpromazine displaced propranolol 
from its binding sites in the rat liver (101). Coadmini-
stration of these drugs would therefore tend to reduce the 
first-pass extraction of propranolol. 
Ethanol and phenobarbital stimulated the in vitro meta-
bolism of propranolol in ~ats (6, 16) and it is possible that 
they might also do so in man o 
capacity of the high affinity 
and would thus be expected to 
traction of propranolol. 
Phenobarbital increased the 
uptake site in rat liver (16) 
increase the first-pass ex-
Smoking increased propranolol metabolism (138) and this 
may result in a lower bioavailability of the drug. 
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1.8.5. Liver disease 
Chronic liver disease can affect the various determinants 
of drug disposition simultaneously. Thus, liver disease 
results in a reduced hepatic metabolism (reduced protein syn-
thesis), a decrease in overall hepatic blood flow and the 
shunting of blood around or within the liver. The effect of 
liver disease on drug elimination has been comprehensively 
discussed in recent review articles (22, 34, 126). 
The extraction of propranolol is reduced in patients 
with cirrhosis in proportion to the severity of the disease 
(107). An increased systemic availability (54%) was found in 
these patients compared to controls (38%) (118) and a re-
duction in extraction ratio to as low as 0,41 has been re-
ported (116). 
While a reduction of Cl. t occurred in chronic cirrhosis in 
(116, 118, 97), portasystemic shunts also contributed to the 
reduction in extraction ratio and first-pass effect. 
The extraction ratio of propranolol was reduced in 
isolated perfused rat livers made cirrhotic by chronic carbon 
tetrachloride inhalation (133). The unexpected finding of a 
reduced (rather than increased) extraction ratio with de-
creasing blood flow in these livers was attributed to a 
shunting of the blood from normally functioning hepatocytes 
to non-functioning tissue (intact hepatocyte theory) (133). 
1.8.6. Hypothermia 
Hypothermia can substantially alter the pharmacokinetics 
of propranolol both in vivo (108, 93) and in vitro (66) by 
decreasing metabolism. This would suggest that temperature 
changes may affect first-pass metabolism. 
1.8.7. Renal disease 
A single oral dose of propranolol, although readily ab-
sorbed in patients with renal disease, underwent a reduced 
first-pass extraction (58). However, after multiple dosing, 
there was an increased extraction ratio (33), possibly owing 
to enzyme induction. 
With pindolol there was a reduced bioavailability in 
patients with renal disease but this resulted from a 
diminished gastrointestinal absorption (56, 84). 
1.8.8. Thyroid disease (Hyperthyroidism) 
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The data in hyperthyroid subjects have been conflicting. 
Feely et al found an increased metabolism and extraction 
ratio of propranolol in hyperthyroid patients (91) while 
others found no change of pharmacokinetics in such patients 
(92). 
1.8.9. Cardiac disease 
The clearance of lignocaine (a very high clearance drug 
like propranolol) was reduced in patients with cardiac failuie 
and cardiogenic shock (following myocardial infarction) as a 
result of reduced hepatic blood flow and impaired metabolism 
(36, 74). 
It is probable that the extraction of propranolol ~ay be 
similarly affected in these conditions. 
1.8.10. Coeliac disease 
There is an increased rate of absorption of propranolol 
in patients with coeliac disease (9, 10). The increased plasma 
levels in these patients has been attributed to saturation 
of the first-pass extraction (10), although others have 
suggested that these elevated levels result from a redistri-
bution of the drug from the red blood cells into the plasma. 
1.8.11. Inflammatory diseases 
o( 1acid glycoprotein binds cationic drugs such as pro-
pranolol. The increase in oc 1 acid glycoprotein in certain in-
flammatory diseases (Crohn 1 s disease and rheumatoid arthritis) 
resulted in an enhanced binding of propranolol to this glyco-
protein (9, 103, 105). 
Schneider et al observed that patients with these diseases 
had a reduced oral clearance (intrinsic clearance) of proprano-
lol with plasma levels up to seven times higher than normal 
(9, 104). They made the interesting suggestion that the 
binding of propranolol to glycoprotein somehow protect~d the 




2.1. General Principles of the Isolated Liver Perfusion Model 
The isolated rat liver perfusion has been used extensively 
in metabolic studies as well as studies investigating drug 
disposition and metabolism. Basically the technique involves 
cannulation of the portal vein allowing inflow of perfusion 
medium followed by removal of the liver from the carcass and 
its perfusion in a cabinet where physiological temperature, 
pH, oxygen and carbon dioxide tension are maintained. 
Studies which use isolated microsomal systems to measure 
drug metabolism cannot meaningfully supply information on 
parameters such as hepatic extraction and drug clearance which 
depend on liver blood flow and tissue distribution. 
However an isolated liver perfusion is ideal for studying 
hepatic drug clearance because: 
(i) flow can be accurately calculated; 
(ii) extraction can be measured directly; 
(iii) oral and intravenous administrations can be 
simulated; and 
(iv) the simple two-component system (liver &nd 
perfusate) enables hepatic extraction and 
clearance to be studied without contri-
butions from other organs of elimination. 
The duration of perfusion has varied with the requirements 
of the investigator. The liver is viable for at least 2 - 3 
hours (61, 62) and livers have even been perfused for up to 
6 hours (35). 
Normal liver function is maintained during the perfusion. 
Karly et al have shown that bile was secreted at nearly the 
same rate during perfusion as by anaesthetised rats (59). 
The water content of the liver remained within the range ob-
served in intact animals. There was no appreciable haemolysis 
during perfusion and the sodium ion concentration of the 
medium did not change (59). Although there was a slight 
increase in potassium ion concentrations after 11 hours with 
a greater increase after 21 hours, this change was similar 
from one liver to the next (59). 
Rowland has f ound a good correlation between the drug 
clearance calcula t ed using an isolated liver perfusion and 
the clearance calculated in vivo in the rat (42, 54). 
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The isolated liver perfusion model is an in vitro model. 
Caution is required when extrapolating results in absolute 
terms to the in vivo situation. Nevertheless, if the per-
fusions are carried out with care and if the conditions (e.g. 
temperature (66, 108) and perfusate volume (44, 78)) remain 
constant from one perfusion to the next, the technique can 
be reliably used to compare the extraction of two drugs. 
2.2. Practical Applications of the Isolated Liver Perfusion 
Model 
All perfusions were carried out in the Department of 
Medicine, University of Cape Town Medical School. Before the 
experiments reported in this study were performed, I had spent 
several months developing and perfecting the surgical tech-
niques and the appropriate methods (see also section 2.3.). 
2.2.1. Introduction 
Tha ~erfusion model used was based on the method of 
Miller et al (35) with modifications to reduce the time of the 
operation by Kerly et al (59) and Hems et al (63). This model 
has been used by workers in the Department of Medicine (61, 
62). 
The model differs from that used by Shand and his 
colleagues (17, 32, 19). These workers pumped the perfusate 
through the liver at a constant flow. In my perfusions the 
liver was always at a constant pressure comparable to that in 
the intact animal and the liver determined its own flow de-
pending on its size and the cannulation of the portal vein. 
This is thought to represent a more physiological situation. 
It is possible that under conditions of high pressure per-
fusion the entire liver may not be perfused. furthermore, 
forced pumping may damage the liver. 
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My liver perfusion experiments lasted for only 90 minutes. 
This time was well within the time limits of viability reported 
by other workers. 
2.2.2. Apparatus 
The glass-fronted insulated perfusion cabinet was built 
in the Department of Medicine. A labelled diagram of the 
apparatus is shown in Fig. 12. 
The heating element (h) ensured that the cabinet was kept 
at a temperature of 38°C. 
The cabinet was humidified by means of steam from boiling 
water in a flask which was fad into the cabinet. The air was 
circulated by a fan. 
The glass reservoir (r) had two openings for the inflow 
and outflow tubing as well as an opening for the oxygenation 
tubing and a wider opening for sample collection. 
The oxygenation chamber or glass lung (o) consisted of 
five involuted chambers. The lung is constructed so that 
flow is retarded which, together with the involuted nature of 
the glass walls, ensured that the perfusion medium spread out 
as a thin film and received adequate oxygenation. 95% o2 • 
5C0 2 , after being bubbled through water, entered the glass 
lung as shown in the diagram. 
The liver (1) was placed on a piece of wire gauze on a 
glass plat9 {g) which fitted into the reservoir as shown in 
the figure. The portal vein cannula (c) fitted onto the end 
of the glass lung. 
Filters (f), which collected any small clots, were placed 
at the points shown in the figure-
Flexible vinyl tubing was used for connecting the 
apparatus. 
The perfusion medium was pumped to the glass oxygenator 
by a Sarna Model 5500 pump (p) and thereafter flowed through 
the liver at a rate determined by a) the liver size, b) the 
bore of the portal vein cannula and c) the pressure head. 
The latter (d) was kept constant at 16 cm of water by ad-
justing the clamp (b) in the overflow bypass (e) so that the 
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fig. 12. The Perfusion Slstem 
A = portal vein sample b = clamp 
8 = hepatic vein sample k = bile duct cannula 
1 = liver s = pressure side-arm 
r = reservoir d = pressure head p = pump g = glass plate 
0 = thin film glass eixygenator C = portal vein cannula f = filter e = overflow bypass 
a = tap h = heating element 
perfusate did not build up in the glass lung over the 16 cm 
mark. The overflow bypass drained back into the reservoir. 
The outflow of perfusate from the hepatic vein fell 
directly into the reservoir which was continuously mixed by 
a magnetic stirrer. 
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The perfusion medium was 20% rat blood BO% KREBS buffer. 
Heparinised blood was obtained by cardiac puncture from Long-
Evans rats under diethyl ether anaesthesia. KREBS buffer con-
sisted of 118,3 mM NaCl; 4,69 mM KCl; 2,52 mM CaC12 ; 
1,18 mM MgS0 4 .?H20; 25 mM NaHC0 3 and 1,18 mM KH 2Po 4 according 
to Shand et al (16). The buffer was freshly made up every 
morning. 
100 ml of blood-KREBS perfusion medium was circulated and 
oxygenated in the cabinet for 20 minutes before the liver was 
introduced into the system. 
2.2.3. Surgical procedures 
This part of the procedure was carried out with the ex-
tremely able assistance of Mr M. Parker of the Department of 
Medicine, University of Cape Town. 
Male Long-Evans rats of approximately 300 g were operated 
on under diethyl ether anaesthesia. When the depth of 
anaesthesia was satisfactory, the rat was secured on an oper-
ating platform. 
An incision was made down the length of the bloodless 
abdominal midline and two lateral incisions made to expose the 
abdominal cavity. The cavity was washed with warm saline 
throughout the procedure to prevent the tissues from drying out. 
The stomach was carefully freed from the liver and the 
oesophagus cut in close proximity to the diaphragm. The liver 
lobes were covered with a swab moistened with warm saline. 
The common bile duct was exposed and cannulated with fine 
portex tubing, ensuring that the side branches of the duct were 
not obstructed. 
The abdominal contents were then moved over to the right. 
This exposed the portal vein. 
Two ligatures were placed around the portal vein about 
two centimetres apart and left untied. The two collateral 
veins were tied off tightly. 
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The portal vein cannula was connected up to a bottle of 
plasmalyte B so that the warm liquid dripped slowly from it. 
From then on the experiment proceeded as quickly as possible. 
The lower ligature around the portal vein was secured. 
An incision was made just proximal to the top ligature and 
the vein was cannulated. This cannula was secured after en-
suring that all the liver lobes were perfused. This could be 
observed because the lobes lightened in colour as the plasma-
lyte B washed through the liver. 
The hepatic veins were cut flush with the liver and then 
the perfusion rate of plasmalyte B was increased slightly. 
The liver was rapidly dissected out, taking care to keep 
handling of the liver to a minimum. 
Any adhering fat was trimmed from the liver and the 
organ was connected to the perfusion system via the portal 
vein cannula. 
The liver lobes were carefully spread out and the liver 
arranged so that the portal vein cannula was not twisted and 
the blood-KREBS could issue freely from the hepatic vein. 
With practice, the time taken from the incision in the 
portal vein to the establishment of the liver in the cabinet 
was usually under t~o minutes. Shock and anoxia were thus 
kept to a minimum. 
The liver was allowed to equilibrate for 30 minutes be-
fore the actual experiment began. 
2.2.4. Experimental Steps 
After equilibrating the liver for 30 minutes, 5 mg of 
the drug dissolved in 3 ml of 20% blood - BO% KREBS were in-
jected as a single bolus into the reservoir. This simulated 
an intravenous administration of drug. See Fig. 8, section 
1.4.11. 
Samples of about 300141 were taken from just above the 
liver (the portal vein samples) by extending a piece of tubing 
down the pressure side-arm at point A in Fig. 12. Immediately 
afterwards samples were collected from the effluent drops 
before they reached the reservoir (hepatic vein samples), 
point 8 in fig. 12. Samples were taken 1, 3, 5, 10, 20, 30, 
40 and 60 minutes after injection of the drug. 
The kinetics of drug elimination are not appreciably 
affected if the sampling volumes are kept as small as they 
were in my experiments (78). 
Perfusate flow was calculated by collecting and timing 
the drops from the hepatic vein ,when samples were 
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collected. The volume of the sample was obtained by weighing 
and this volume was used to calculate the flow rate in ml/min. 
Perfusate flow varied from 1,83 - 5,05 ml/gram wet liver 
tissue/minute. (21 ml/min - 60 ml/min.) Because of the less 
viscous nature of my perfusate this flow range is greater 
than the range of about 1 - 3 ml/g/min obtained with 100% 
~hole blood. Perfusions were only acceptable if the flow rate 
was reasonably constant throughout the experiment. 
Bile flow rate ranged from 15 seconds per drop at the 
beginning to 90 seconds per drop at the end of the perfusion 
although the range varied from one perfusion to the next. If 
the bile did not flow spontaneously and in regular droplets, 
the perfusion was discarded, although in most cases a sluggish 
bile flow was corrected by rearranging a twisted bile cannula. 
The pH was kept constant between 7,4 and 7,6 - if 
necessary, by the addition of 4,2% sodium bicarbonate. 
The packed cell volume was measured at both the beginning 
and at the end of the perfusion to check that there was no 
appreciable haemolysis. 
A liver perfusion was only accepted for inclusion in 






adequate bile production; 
adequate perfusate flow; 
the absance of visible infarcts and/or liver 
swelling; . and 
a stable portal pressure. 
It is relevant to note that during the perfusions with 
pindolol a blue pigment appeared in the bile resulting in a 
dark green coloration. This was due to a metabolite of 
pindolol (metabolite VIII, Fig. 10, section 1.6.3) and it 
was a clear demonstration of the presence of an actively 
metabolising liver system. This was additional evidence of 
the viability of the perfusion model. 
When the perfusion was complete the liver was weighed. 
Samples were assayed for drug on the same day, or re-
frigerated overnight for analysis the next day. 
2.3. Additional notes on Overflow Bypass 
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One apparently limiting factor of my perfusion model was 
that there was an overflow bypass (e, Fig. 12). 
This bypass was designed to regulate the effects of flow 
on the pressure head (d, Fig. 12). Since the liver blood 
flows in my experiments varied between 21 ml/min and 60 ml/min 
the pressure tended to build up above the 16 cm mark, more 
particularly where the rate of liver blood flow was slow. In 
order to maintain the constant pressure head of 16 cm of 
water, it was necessary to drain off the excess blood volumes 
into the overflow by regulation of clamp b (Fig. 12). This 
blood flowed directly back to the reservoir and thereby 
escaped the liver. Such an arrangement gave a good approxi-
mation to the in vivo situation where a proportion of an 
intravenous dose does not pass through the liver in the first 
cycles. 
The incorporation of the bypass tube into the perfusion 
would not have affected the pharmacokinetics. The extraction 
ratio which was obtained was an average figure calculated over 
a period of 60 minutes when all of the injected drug had been 
eliminated. 
In any case, where flow was a factor influencing a 
pharmacokinetic parameter, that parameter was always analysed 
both in the overall propranolol and pindolol groups and in 
selected subgroupsin which flow was controlled. It will be · 
noted (see Results section) that the statistical significance 
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of the findings obtained in the complete groups was unchanged 
in the flow-matched subgroups. This confirmed that the varying 
amounts of perfusate entering the bypass had little, if any, 
impact on the interpretation of the data. 
furthermore, all the portal vein samples for drug assay 
were taken from a point below the overflow bypass (point A, 
Fig. 12) and this ensured that these samples were derived 
from blood that was definitely routed through the liver. 
2.4. Additional notes on Perfusion Method selected 
In the preliminary stages of this study I tried two 
variations of the experimental method: 
(i) I injected the total dose into the reservoir and 
allowed the entire volume to perfuse through the liver only 
once with clamp b (Fig. 12) completely closed. I collected 
the entire emergent effluent and assayed this volume for 
total drug, thus obtaining a measure of the total amount of 
drug extracted. 
This method was unsuitable because there was no control 
over pressure and flo~ and rate of flow has a major effect 
on extraction ratio. There were also practical difficulties 
in ensuring that the total volume was in fact collected since 
small amounts remained entrapped in various parts of the per-
fusion system. At the end of the perfusion, air bubbles 
formed and passed through the liver. 
Furthermore, this method would have limited the pharmaco-
kinetic parameters that could have bee n measured. 
(ii) Shand and colleagues (17), in their perfusion studies, 
conducted serial perfusions. They first injected the total 
dose into the reservoir; this simulated intravenous admini-
stration. This was the method which I adopted in my study. 
They followed this (after one hour) with an injection of the 
total dose into the portal vein; this simulated oral admini-
stration of drug. 
I, too, attempted the latter mode of administration but 
had practical difficulties with the injection of drug into the 
portal vein. It was difficult to control the rate of infusion 
of the drug and,if the rate of injection was too fast, the 
drug escaped into the overflow before going through the 
liver. 
2.5. General Introduction to Analytical Methods 
2.5.l. Propranolo l 
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The fluorometric method of Shand et al (31) was used in 
this study to determine propranolol concentrations. This is 
the most widely applied method which has been extensively 
employed since 1970 up till the present day (121, 122, 124) 
not only by Shand and co-workers (14, 16, 17, 18, 19, 43, 50, 
51, 109), but by numerous other investigators (4, 58, 70, 82, 
83, 90, 108). 
(i) Sensitivity 
When the fluorometric method was compared to the high-
performance liquid chromatographic method in human plasma 
assays of propranolol (41), there was an excellent correspond-
ence between the respective determinations only if the 
subject's own blank plasma was used. The existence of a high 
blank reading was confirmed by some (89) but not other 
workers (31, 72). However, in the present study blank and 
standards were prepared in the same blood-KREBS as was used 
in the perfusion expe ximent that day, thus excluding the 
possibility of interference by blank plasma. 
The limit of detection of propranolol has been sat by 
various workers in a range varying from 5 ng/ml to 30 ng/ml 
(2, 72, 68). 
(ii) Specificity 
The specificity of the fluorescent method was originally 
established by Evans et al (16) and Shand et al (31) who 
found no interference by metabolites. 
There are few quantitative data on metabolite concen-
trations in the rat. A major metabolite in man and rat is 
4-hydroxy propranolol but this compound was poorly extracted 
by the method as it is converted to an unextracted conjugated 
derivative during the extraction procedure (59). Moreover it 
has minimal fluorescence in the O,l N HCl in which the samples 
were read (71). Naphthoxylactic acid is a major metabolite 
47. 
in the rat but this was not extracted in the method employed (52). 
Recently more metabolites have been investigated. Of the 
propranolol metabolites only N-desisopropyl propranolol and 
propranolol glycol have shown both significant fluorescence at 
the propranolol fluorescence wavelengths (71, 72) and extraction 
to any extent. However, very small amounts of these meta-
bolites relative to propranolol were detected in human serum 
by gas-liquid chromatography. In the rat N-desisopropyl pro-
pranolol is only an intermediate metabolite in the conversion 
of propranolol to the poorly extracted propranolol glycol and 
to the unextracted naphthoxylactic acid (128). 
In fact, a good correspondence was obtained from proprano-
lol values derived from gas-liquid chromatography and those 
obtained by the fluorometric assay (71), (see fig. 13). Kraml 
et al have performed several thousand fluorometric assays of 
propranolol and experienced only a 1% interference. They 
were satisfied that this method was specific both with whole 







































PLASMA PROPRANOLOL CONCENTRATION (ng/ml) 
GAS CHROMATOGRAPHIC ASSAY 
fig. 13: Comparison of the plasma propranolol 
levels in 22 hypertensive patients as measured 
by the gas chromatographic assay versus those 
determined fluorometrically. The line pictured 
was fitted to the data using linear regression 
analysis (after Pritchard et al (71)). 
2.5.2. Pindolol 
The fluorometric method of Pacha (26) uas used in this 
study to determine pindolol concentrations. This method has 
had extensive application in both clinical and experimental 
studies (3, 11, 13, 21, 39, 40, 56, 64, 84, 113). 
(i) Sensitivity 
The lower limit of detection has been claimed to be 
from 5 ng - 20 ng/ml (26, 39). 
(ii) Specificity 
48. 
Kiechel (7) has shown with thin-layer chromatography 
that all the polar metabolites of pindolol remain in the 
NaOH-phase during extraction and that only unchanged pindolol 
enters the HCl-phase,which is the one used for fluorometric 
measurements. He did find traces of an unidentified metabo-
lite in the HCl-phase which consisted of small amounts of 
the side-chain of pindolol. However the fluorescing agent 
reacts specifically and exclusively with the indole nucleus 
so that this metabolite would not interfere with the assay. 
It can thus be concluded that metabolites of pindolol 
do not interfere with the fluorometric determination of the 
parent compound. 
2.6. Analytical Methods 
2.6.1. Measurement of Total Drug Blood Concentrations 
Equations used to calculate the extraction ratios, in-
trinsic clearances and hepatic clearances contain the term 
hepatic blood flow. In order to maintain consistency, drug 
concentrations in the blood rather than in plasma are 
measured (27, 94). 
In addition, the extraction ratios for both propranolol 
and pindolol in the rat are greater than the free plasma 
fraction of the drug (43, 100). In these cases the blood 
actually transports the drug to its site of elimination and 
the relevant kinetic parameters are more meaningfully calcu-
lated from whole blood (or in my case, 20% whole blood - BO% 
KREBS) concentrations (24, 33, SO, 54, 98, 132). 
49. 
2.6.2. fluorometric Determination of Propranolol 
Propranolol was assayed according to the method of Shand 
et al (31) with minor modifications in the volumes used. This 
method is efficient in whole blood as well as plasma (72, 43). 
In order to test the reliability of the assay in 20% 
rat blood-BO% KREBS buffer, a standard graph was done with 
each point in quadruplicate as shown in Graph 1. This shows 
a high degree of consistency in the assay measurements. The 
standard calibration curve was linear to at least 2000 ng in 
500_µ.l of 20% blood-BO% KREBS buffer. The lower limit of re-
liable detection was approximately 100 ng in 500fll of 20% 
blood-BO% KREBS. 
Perfusion sample volumes ranged from 50/ll to 500_fll de-
pending on the expected concentrations of drug (the higher the 
concentration, the lower the sample volume). All samples were 
made up to 500fAl with 20% rat blood-BO% KREBS before ex-
traction. 500)-11 of blood-KREBS were used as a blank and 
three 500,fll aliquots were spiked with 250, 500 and lOOOng of drug 
(dissolved in water) respectively. The 20% rat blood-BO% KREBS 
was the excess of that used in the perfusion earlier in the 
day. The blank and standards were extracted simultaneously 
with the unknown samples. 
The samples were basified with 1 ml of lN NaOH and shaken 
with 10 ml of 1,5% isoamylalcohol, 98,5% heptane for 15 minutes 
on an automatic shaker. 8 ml of the heptane layer were re-
moved and shaken with 4 ml of O,l N HCl for 15 minutes. This 
acid phase was then read in a Perkin-Elmer MPF - 44A Spectro-
fluorimeter at an excitation wavelength of 295 nm (slit 10 nm) 
and an emission wavelength of 360 nm (slit 8 nm). 
Concentrations of drug were corrected for the different 
volumes extracted and expressed infLg/ml. 
2.6.3. fluorometric Determination of Pindolol 
Pindolol was assayed according to the method of Pacha (26) 
with minor modifications in the volumes used. This method is 
reliable in whole blood as well as plasma (56, 84). 
In order to check the reliability of the assay in 20% rat 
blood-BO% KREBS buffer, a standard graph was done with each 
point in quadruplicate as shown in Graph 2. This shows a 
high degree of consistency in the assay measurements. The 
standard calibration curve was linear to at least 2000 ng/ 
500,.u.l 20% rat blood-BO% KREBS buffer. The lower limit of 
reliable detection was approximately 100 ng/500)-ll· 
50. 
Perfusion sample volumes ranged from 50,P-l to 500,PLl 
depending on the expected concentrations of drug (the higher 
the concentration, the lower the sample volume). All samples 
were made up to 500,,Ul with 20% rat blood-BO% KREBS before ex-
traction. 500Jll of blood-KREBS were used as a blank and 
three 500,,U.l aliquots were spiked with 250, 500 and 1000 ng of 
drug (dissolved in water) respectively. The 20% rat blood-BO% 
KREBS was the excess of that used in the perfusion earlier in 
the day. The blank and standards were extracted simultaneously 
with the unknown samples. 
The samples were basified with 1 ml 1 N NaOH and shaken 
with 10 ml of diethyl ether for 15 minutes on an automatic 
shaker. B ml of the diethyl ether layer were removed and 
shaken with 4 ml of O,l N HCl for 15 minutes. 3 ml of the 
acid extract was then heated in a water bath at so 0 c for 
30 minutes with 200 fl ofa 0,5% solution of phthaldialdehyde 
in MeOH. After cooling, the fluorescence of the solutions 
was stabilised by the addition of 500JL1 of a 1% solution of 
ascorbic acid in water. The fluorescence of the solutions 
was measured in a Perkin-Elmer MPF - 44A Spectrofluorimeter 
at an excitation wavelength of 390 nm (slit 10 nm) and an 
emission wavelength of 440 nm (slit B nm). 
Concentrations of drug were corrected for the different 
volumes extracted and expressed in .p.g/ml. 
All the extractions were done in glass tubes with ground 
glass stoppers because rubber stoppers were found to alter the 
distribution of drug between red blood cells and plasma (29). 
Periodically the tubes were cleaned in chromic acid in addition 
to the normal washing procedure. The tubes were well rinsed 
with twice-distilled water and all the solutions were made up 




3.1. Liver Blood Flow 
As can be seen from Tables la and b, there was little vari-
ation in hepatic blood flow during the perfusions and an 
average value was taken for the purpose of the calculations. 
3.2. Drug~Concentration-versus-Time Curves 
Drug concentrations in 20% rat blood - BO% KREBS buffer 
~/ml) were plotted against time on semi-logarithmic graph 
paper (Graphs 3a - 9a for propranolol and 10a - 16a for 
pindolol). The best straight lines were fitted by eye and, 
where there was doubt, I took a consensus from two independent 
observers as to the most appropriate positioning of the line. 
Points derived from the above straight lines were trans-
posed on to linear graph paper to obtain drug-concentration-
versus-time curves for the portal vein (Graphs 3b - 9b for 
propranolol and lOb - 16b for pindolol) and for the hepatic 
vein (Graphs 3c - 9c for propranolol and 10c - 16c for 
~indolol). 
Areas under the drug-concentration-versus-time curves 
were calculated from the linear graph paper by counting the 
squares underneath the curves as shown in Graphs 3b and 3c 
(for propranolol) an d 10b and 10c (for pindolol). 
3.2.1. Sensitivity of the Assays 
I found that the assays for both propranolol and pindolol 
were sensitive and reproducible to a lower limit of 100 ng/ml 
20% blood-BO% KREBS. Between 100 and SO ng/ml readings were 
not always reliable and below SO ng/ml they were generally 
inconsistent and unreliable. 
However, the majority of concentrations obtained in my 
experiments were above the 100 ng/ml limit: those that fell 
below occurred at the tail-end of the drug-concentration-versus 
time curve {at 40 and 60 minutes) where an inspection of the 
52. 
Graphs (3b,c - 16b,c) shows that their contribution to the 
overall area-under-the-curve values was negligible; in fact, 
some of the concentrations at 40 and 60 minutes were un-
detectable by the assay. 
3.2.2. Specificity of the Assays 
The possibility of drug metabolites interfering with 
the fluorescence of unchanged drug was considered. If inter-
fering metabolites had been present they would have accumu-
lated with time (and particularly so in the emergent hepatic 
vein perfusate) and falsely inflated the readings at the 
terminal end of the perfusions. Inspection of Graphs 3a - 16a 
shows that this did not occur; all readings had declined to 
near zero by 60 minutes. 
3.2.3. Semi-logarithmic plots of Propranolol 
Semi-logarithmic plots of blood-KREBS propranolol con-
centrations-versus-time in the portal vein produced a biphasic 
curve with an~ and i phase reflecting the distribution and 
elimination processes respectively (Graphs 3a - 9a). 
3.2.4. Semi-logarithmic plots of Pindolol 
Semi-logarithmic plots of blood-KREBS 
centrations-versus-time in the portal vein 
a single straight line (Graphs 10a - 16a). 
pindolol con-
appeared to yield 
Although these 
blood-KREBS levels may have declined bi-exponentially, the 
initial phase must have been so rapid that my data were in-
sufficient to define that portion of the curve. The results 
were therefore analysed as if the model behaved as a one-com-
partment open system. 
3.2.5. Exclusion of the possibility of drug adherence to 
glass and apparatus material 
Inspection of Graphs 1 and 2 shows that the plot of 
fluorescence intensity against concentration of the standards 
was a straight line which passed through zero. This indicates 
that there was no irreversible adherence of either propranolol 
or pindolol to glass during the extraction. It was also found 
that silanisation of the glass had no effect on the 
fluorescence readings obtained. 
Graphs 3a - 16a clearly demonstrate that when the slope 
of the portal vein concentration-time line for both pro-
pranolol and pindolol was extrapolated back to the y-axis 
to determine the theoretical concentration at t = o, the 
derived figure was very close to the expected concentration 
of both drugs at instantaneous distribution throughout the 
perfusate, i.e. 5 mg of ~rug in 103 ml of blood-KREBS= 
48,5 p.g/ml. This again establishes the validity of the 
assay and excludes the possibility of drug adherence to the 
perfusion apparatus. 
3.3. Abbreviations of Parameters Calculated 
On the basis of the calculated areas-under-the-concen-
tration-time curves a number of parameters were derived and 
compared for propranolol and pindolol. 
53. 






















hepatic extraction ratio (first-pass ex-
traction) 
area under the drug concentration-versus-
time curve for the portal vein 
area under the drug concentration-versus-
time curve for the hepatic vein 
hepatic intrinsic clearance of total drug 
hepatic clearance of tote.l drug 
total dos& of drug administered 
hepatic flow rate 
elimination half-life 
apparemt vglume of distribution 
concentration at time zero 
54. 
Statistical Abbreviations(!) 
t = t dis t ribution (Student's t test) 
r = correlation co-efficient (product moment) 
p = probability 
NS = not significant 
df = degrees of freedom 
3.4. Heeatic extraction ratio (E) 
This ratio is equal to the first-pass extraction and 
reflects the fraction of the dose of drug removed during its 
first passage through the liver. 
Three different formulae (see below) were used to calcu-
late E and the three values obtained were averaged. 
(i) E = 
(ii) E = 
where 
(iii) E = 
AUCPV - AUCHV 
AUCPV 
Clint 
Q + Clint 
, ... 1 (2) -





(In the perfusion model, after intravenous 
administration, the AUCPV corresponds to the 
AUCs in the intact animal.) 
Tables 2a and 2b show the extraction ratios for pro-
pranolol and pindolol respectively. There is no significant 




The formulae for the etatistical tests employed are listed 
in the Appendix. 
Calculation of Clint values obtained are set out in section 
3 • 5 .. 
However, the mean extraction ratio for propranolol was 
0,71 and that for pindolol was 0,50. This difference is 
highly statistically significant (t = 5,42; p-<0,001) and it 
indicates that the first-pass effect is greater in the case 
of propranolol. 
3.4.1. Flow and Extraction Ratio 
55. 
The individual perfusions in both the pindolol and pro-
pranolol groups are ranked from A to Gin order of increasing 
flow, as shown in Tables 2a and 2b. 
With pindolol (Table 2b) there is a highly significant 
negative correlation between flow and extraction ratio 
(r = -0,BB; t = 4,15; p<0,01). There was a similar trend 
with propranolol for increasing flow to be accompanied by a 
reduced extraction ratio (Table 2a) but this correlation did 
not attain significance (r = -0,74; t = 2,50; p<0,10). 
An inspection of Table 2b shows that for pindolol in-
creasing flow is accompanied by a progressive decrease in ex-
traction ratio except in the case of perfusions D and F where 
the respective intrinsic clearances exceed the mean intrinsic 
clearance. With propranolol (Table 2a) there is also a pro-
gressive decrease in E with increasing flow except in per-
fusions D and E where the respective intrinsic clearances are 
well below the mean intrinsic clearance. 
Although there was no significant difference in the 
mean flow rates between the propranolol and pindolol groups, 
there was a difference in the range of flows (35 ml/min -
60 ml/min for propranolol; 21 ml/min - 60 ml/min for pindolol 
- Tables 2a and 2b). For this reason it was decided to ex-
clude the possibly distorting effects of flow on extraction 
ratio by taking a subgroup of perfusions from both groups 
with ioentical, or nearly identical, flow rates, as shown in 
Table 2c. The results again clearly show a marked difference 
in E between propranolol (0,69) and pindolol (0,45). (t = 5,66; 
p<0,01.) 
The proportionately more ma=ked influence of flow rate 
on the extraction ratio of pindolol is ahown in Table 2c. 
The 71% and 67% increase in flow rate for the propranolol 
and pindolol groups respectively was accompanied by a 12% 
decrease in E for propranolol and a 28% decrease in E for 
pindolol. 
3.5. Hepatic Intrinsic Clearance (Total Drug) (Clint) 
56. 
This parameter reflects the maximum inherent ability or 
capacity of the liver to extract drug from blood assuming the 
drug is not limited in its access to hepatic cells by dis-
tributional factors (such as flow and binding to blood con-
stituents). 
Two different formulae (see below) were used to calcu-
late Clint and these two values were averaged. 
(i) 





1 - E 




The total hepatic intrinsic clearances were expressed in 
ml/gram of wet liver tissue/minute. 
Tables 3a and 3b show the intrinsic clearances for pro-
pranolol and pindolol respectively. 
The mean intrinsic clearance for prapranolol was 
10,44 ml/g/min and that for pindolol was 3,42 ml/g/min. This 
difference is very highly significant. (t ~ 11,56; p<0,001) 
3.5.!. Flow and Intrinsic Clearance 
Tables 3a and 3b show that there is no correlation be-
tween hepatic flow and total hepatic intrinsic clearance in 
either ~he propranolol or the pindolol groups. (r = 0,23; 
t = 0,54; NS for propranolol; r = 0,48; t = 1 1 24; NS for 
pindolol) 
57. 
3.6. Interrelationships between Extraction Ratio, Intrinsic 
Clearance and Hepatic Flow 
from equation 13, 
1 
= l + Q 
E Clint 
Graph 18 shows a plot of 2:.. versus Q (where Q is expressed in 
ml/gram of liver/minute),Efor both propranolol and pindolol. 
E was calculated from equation 10 (E = Clint ). The slope 
Clint+ Q 
of the line was fitted by linear regression analysis and was 
found to have an intercept of 1,07 in the case of propranolol 
and 1,05 in the case of pindolol. 
The slope of the propranolol line <ci~ ) was o,oaa and 
int 
that of the pindolol line was 0,306. Hence the Clint (sl~pe) 
is greater for propranolol (11,36 ml/g/min) than for pindolol 
(3,27 ml/g/min). 
This graph also shows that E decreases with flow to a 
proportionately more marked extent for pindolol than propranolol. 
Equation 13 (above) 
E = 
can be rearranged 
Cl. t in 
Q + Cl. t in 
to give 
(equation 10) 
Table 4 shows the interrelationships betwean the indi-
vidual flow rates (expressed in ml/g/min) y intrinsic clearances 
and extraction ratios. The values for intrinsic clearance are 
those derived from the formula Div (section 3.3.) and thus 
AUCHV 
were not directly derived from equation 13. Similarly, the 
values for E were an average of formulae (i) and (iii) (section 
I 
3.4.) and were therefore ~ot derived from equation 13. 
When flow is greater than the intrinsic clearance, then 
the extraction ratio is greater than 0,5 (equation 11). As is 
evident in Table 4 all the intrinsic clearances for propranolol 
exceeded the hepatic flow and all the extraction ratios ex-
ceeded 0,5. 
In the case of pindolol, where the intrinsic clearances 
58. 
exceeded the hepatic flow, E was greater than 0,5 (perfusions 
A and B); where the intrinsic clearances were less than flow, 
E was less than 0,5 (perfusions E and G); and where the in-
trinsic clearances were approximately equal to hepatic flow, 
E was approximately equal to 0,5 (perfusions C, D and F). 
3.7. Hepatic clearance (Total Drug) (ClH) 
This parameter is an index of the actual perfusate volume 
cleared of d~ug by the liver in unit time. 
Two different formulae (see below) were used to calculate 
ClH and these two values were averaged and expressed as 










(In the perfusion model AUCPV 
corresponds to ALIC in the 
s 
intact animal.) 
Table 5a and 5b show the hepatic clearances for proprano-
lol and pindolol respectively. 
The mean hepatic clearance for propranolol was 2,47 ml/g/ 
min and that for pindolol was 1,56 ml/g/min. This difference 
is highly significant. (t = 4,81; p<J),001) 
3.7.1. Flow and Hepatic Clearance 
There was a significant correlation between flow and 
hepatic clearance in the pindolol group (r = 0,87; t ~ 3,91; 
p<0,05 - Table Sb.) With propranolol there was Every hignly 
significant correlation between flow and hepatic clearance 
(r = 0,97; t = 9,73; p(0,001 - Table 5a.) 
An inspection of Table 5a and 5b shows that increasing 
flow is accompanied by a progressive increase in hepatic 
clearancs in all cases except those in which the intrinsic 
clearances are less than flow in the case of pindolol (per-
fusions E and G) and in which the intrinsic cleara~ces are 
below the mean ln the case of propranolol (perftisions D and E). 
Table 6 represents two subgroups of perfusions from 
the propranolol and pindolol groups respectively where rate 
59. 
of flow is controlled. It is evident that the mean difference 
in hepatic clearance between the drugs is still highly statis-
tically significant (t = 3,84; p~0,01) even when the possibly 
distorting effects of different flow rates are excluded. 
The proportionately more marked influence of flow rate 
on the hepatic clearance of propranolol is shown in Table 6. 
An increase in flow of 71% for propranolol (35 ml/min to 
60 ml/min) produced an increase in ClH of 49% whereas a 67% 
flow increase for pindolol (36 ml/min to 60 ml/min) produced 
an increase of only 15%. 
3.8. Elimination Half-life (t~l 
The elimination half-life (t1~) was calculated from the 
elimination(~) phase in both the portal vein and the hepatic 
vein logarithmic drug concentration-time plots. It represents 
the time taken for any given blood-KREBS drug concentration in 
the~ phase to fall by 50 per cent. 
Table 7 shows the tiE for tha propranolol and pindolol 
groups in the portal and hepatic veins respectively. 
The t-to<. of pro prano lo l was o bta ine d f ram the slope (o<.) 
of the line calculated from the method ~f residuals as shown 
in Graphs 3a - 9a. This method plotted the difference between 
the actual concentration at a given time and the concentrations 
obtained from the extrapolated portion of the ~-slope at the 
same time. 
The t!o<. was measureo by the time taken for a given con-
centration on the o£ slope to fall by 50 per cent. Table 7 
shows these t!o(. values. "Che ttcx.of proprannlol was very short 
( 1, 0 minutes) while the t! i was much longer ( 5, 2 minutes, 
portal vein; 5,0 minutes, hepatic veiG). 
The t! J for pindolol was 4,1 minutes ano 3,8 minutes in 
the portal and hepatic veins respectively. 
3.8.1. Elimination Half-life and Flow 
Table 7 shows the relationship between flow and half-life 
for both propranolol and pindolol in the portal vein. There 
60. 
was no correlation between flow rate and t!J for the proprano-
lol perfusions (r = -0,47; t = 1,18; NS). There was a highly 
significant negative correlation between flow rate and ti~ 
for the pindolol perfusions (r = -0,93; t = 5,64; p<o,01J. 
A correlation was also obtained between flow rate and 
the half-life of theot-phase for propranolol. A highly signi-
ficant negative correlation emerged between these two variables 
(r = -0,93; t = 5,67; p<0,01). 
Table 7 shows the relationship between flow and half-life 
in the hepatic vein. There was no correlation between flow 
rate and ttJ for the propranolol perfusions (r = -0,63; t = 1,82; 
NS). There was a highly significant negative correlation be-
tween flow rate and tt1 for the pindolol perfusions (r = -0,91; 
t = 5,09; p(0,01). 
3.9. Apparent Volume of Distribution (Vdl 
This parameter reflects the apparent volume into which 
the drug appears to be distributed. 
Two different formulae (see below) were used to calculate 
Vd and these two values were averaged and expressed as 
ml/gram of wet liver tissue. 
(i) vd = ClH . t~ 
0,693 2 {equation 6) 
(ii) Va D. = iv 
C {equation 2) 0 
where C i& the drug concentration at time zero, derived (in 0 
the case of propranolol) by extrapolation of the ~-phase slope 
to the y-axis, as shown in Graphs 3a - 9a. 
Table 8 shows the apparent volumes of distribution for 
propranolol and pindolol. The mean Vd of propranolol 
(21,23 ml/g) is highly si£nificantly g~eater than pindolol 
(8 9 72 ml/g) (t = 9,13; p<0,001). 
3.10. Instantaneous Extraction Ratios 
This ratio was calculated from the following formula: 
E = CPV - CHV 
CPV 
where CPV = drug concentration in the portal vein 
and CHV = drug concentration in the hepatic vein. 
These concentrations were derived from the mean drug con-
centration-time-curves shown in Grapt-s 17a and b. 
Table 10 shows the instantaneous extraction ratios for 
propranolol and pindolol at time points throughout the per-
fusion. 
3.11. Capacity of the high affinity site of propranolol 
The capacity of the high affinity site of propranolol 
was calculated from the amount of drug extracted after 
5 minutes divided by the liver weight. 
These values expressed in µg/g wet liver tissue are 
shown in Table 9. The mean capacity was 329 jlg/g of liver. 
3.12. Summary of Results 
1. Graphs 17a and bare semi-logarithmic plots of the mean 
concentration values for propranolol and pindolol against 
time in the hepatic and portal veins. Graph 17a shows 
the biphasic curve of propranolol in the portai vein. 
61. 
2. The mean ext ~action ratio for propra~olol was highly 
significantly greater than that for pindo~ol (p~,001). This 
difference occurred evan when flow was controlled (p<D,01). 
While the correlation betwGen flow ano extraction ratio for 
propranolol did not attain significance (p<D,10:~ there was 
a trend in that increasing flow ratios were accompanied by 
decreasing e ~traction ratios. In the case of pinaolol, there 
was a highly statistically significant neg3tive correlation 
between flow and extraction ratio (~<D,01) (section 3.4.). 
3. The mean hepatic intrir.sic clearancE of total drug in 
tr.e blood-KREBS was very highly significantly greater for pro-
pranclol than for pindolol (p<0,001). This parameter was in-
dependent of flow for both propranolol and pindolol (sectior. 
3.5.). 
4. The interrelationships between E, Cl. t and Q 1n 




c1. t 1n 
5. The hepatic clearance of total blood-KREBS propranolol 
was significantly greater than that of pindolol (p~0,001)~ 
62. 
This difference occurred even when flow was controlled (p<0,01). 
There was a positive correlation between flow and hepatic 
clearance and this effect was more marked in the case of 
propranolol (section 3.7.). 
6. The elimination half-life (t!l) of pindolol was shorter 
than that of propranolol. There was a highly significant 
negative correlation between flow and t!o<,with propranolol 
(p<0,01) but no significant correlation emerged between flow 
and tti· In the case of pindolol, however, there was a highly 
significant negative correlation between t!~ and flow (p<D,01). 
7. The apparent volume of distribution for propranolol was 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Comparison of the Extraction Ratio of Propranolol and 
Pindolol with flow Rate Controlled 
PROPRANOLOL PINDOLOL 
Q E Q E 
ml/min ml/min 
A 35 0,74 C 36 0,50 
8 42 0,72 D 43 0,51 
E 46 0,66 E 46 0,41 
G 60 0,65 G 60 0,36 
Mean 45,75 0 59(l) , 46,25 0 45(l) , 
(!s.E.M.) (!0,02) (:!:0,04) 




Total Hepatic Intrinsic Clearances of Propranolol 
Q AUCHV(l) (i) Clint (ii) Clint Clint Cl. t in 
= D. = QE ( Aver-
Liver12 ml/min ,.ug/m~ • --ll 
-
age) 
min AUCHV 1 - E ml/min weight 
ml/min ml/min ml/g/ min 
A 35 44 113,64 130,00 121, 82 10,10 
B 42 41 121,95 148,91 135, 43 11,12 
C 44 35 142,86 156,00 149, 43 11,32 
D 45 45 111,11 121,67 116, 39 8,77 
E 46 54 92,59 107,33 99,96 8,72 
r 47 37 135,14 157,35 146, 25 11,52 
G 60 42 119,05 154,29 136, 67 11,51 
Mean 45,57 10 44( 3) , 
(!s.E.M.) (!2,83) (!0,47) 
(1) 
~~j 
There is no correlation between Q and AUCHV (r = -0,086; 
t = D,081; NS). 
for liver weights see Table la. 
Comparisons against pindolol are shown in Table 3b. 
69. 
Table 3b 
Total Hepatic Intrinsic Clearances of Pindolol 
Q AUCHV(l) (i) Clint (ii) Clint Clint Clint 
ml/min p.g/m~. = Div = QE (Aver- LiveJ2 min 
- age) AUCHV 1-E weight 
ml/min ml/min ml/min ml/g/ 
min 
A 21 138 · 36,23 34,26 35,25 3,08 
8 26 137 36,50 42,42 39,46 3,30 
C 36 141 35,46 36,00 35,73 . 2,83 
D 43 111 45,05 54,72 49,89 4,47 
E 46 159 31,45 36,14 33,80 2,41 
f 57 94 53,19 64,28 58,74 5,13 







(1) There is no correlation between Q and AUCHV (r = -0,22; 
t = 0,53; NS). 
for liver weighta see Table lb. 
t = 11,56; p<0,001; df = 12 (against mean total hepatic in-
t~insic clearance of propranolol, Table 3a). 
Table 4 
Relationship between Blood flow 1 Intrinsic Clearance and 
Extraction Ratio for Propranolol and Pindolol 
PROPRANOLOL PINDOLOL 
Q Clint UJ E l2J Q Cl. t ll) in 
ml/g/min ml/g/min ml/g/min ml/g/min 
A 2,90 9,42 0,74 A 
8 3,45 10,01 0,71 8 
C 3,33 10,82 0,75 C 
D 3,39 8,37 0,70 D 
E 4,01 8,07 0,66 E 
f 3,70 10,64 0,71 f 
G 5,05 10,03 0,69 G 









(2) derived fro m the formulae, E = AUCPV - AUCHV 
AUCPV 
D. 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2,50< 2 ) 
(!0,21) 
t = 3,97; p(0,01; df = 6 




C 36 17,93 
D 43 20,81 
E 46 18,30 
G 60 21,31 









1,56( 2 ) 
(!0,12) 
Table 7 
Elimination Half-life for Propranolol and Pindolol 
PROPRANOLOL PINDOLOL 
Portal Hepatic Portal Hepatic 
Q vein vein t,-o( Q vein vein 
ti~ t,-i t,-i t,_ 13 
ml/min min min min ml/min min min 
A 35 6,0 6,0 1,2 A 21 5,2 5,2 
8 42 5,6 5,6 1,1 8 26 5,4 4,8 
C 44 4,6 4,4 1,0 C 36 4,1 3,6 
D 45 5,7 5,0 1,0 D 43 3,8 3,9 
E 46 6,0 5,5 1,0 E 46 4,2 4,0 
F 47 4,0 3,9 0,9 F 57 3,D 3,1 
G 60 4,8 4,4 0,8 G 60 3,2 1,9 
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Table 9 
























Instantaneous Extraction Ratios of 
Propranolol and Pindolol 
PROPRANOLOL PINDOLOL 
Time Ell) Ell) 
minutes CPV - CHV 
CPV - CHV 
CPV CPV 
1 0 99( 2) , 0,75 
3 0 94( 2) , 0,48 
5 0 69( 2) , 0,42 
10 0,26 0,46 
20 0,35 0,53 
30 0,43 0,59 
40 0,52 0,64 
(1) Based on the mean concentration values shown in 
Graphs 17a and 17b. 
(2) These values are the instantaneous extraction ratios 
during the ol-phase. 
77. 
CHAPTER 4 
DISCUSSION AND CONCLUSIONS 
The primary a i m of this study was to compare the first-
pass extraction of the two beta-blockers, pindolol and pro-
pranolol, in view of reports from various sources that pro-
pranolol undergoes a larger first-pass effect. 
78. 
The present project was set up to evaluate the pharma-
cokinetic parameters of the two drugs within the context of 
an isolated rat liver perfusion model. The advantage of the 
latter approach was that these drugs could be tested and com-
pared under identical experimental circumstances. As far as 
is known, this was the first attempt to make direct com-
parisons between propranolol and pindolol in the rat under 
standardised conditions. 
Extraction Ratio 
The results show that the mean extraction ratio (first-
pass effect) for propranolol (0,71) was highly significantly 
greater than for pindolol (0,50) (p<0,001). The figure of 
0,71 for propranolol was very close to the mean extraction 
ratio value of 0,68 (at a flow rate of 20 ml/min) obtained 
from various rat liver perfusion studies (15, 17). 
Very little information exists on the extraction ratio 
of pindolol in the rat, and the only valus available (ob-
tained from Sandoz Laboratories - unpublished data) was one 
of 0,5 which is the same figure as that derived from my ex-
periments. 
Most of the work on pindolol relates to man where the 
extraction ratio (first-pass effect) was 0,13 (4), 0,10 (21), 
0,23 (56) and 0,47 (39). Except for the latter, all the 
other figures are considerably lower than that calculated by 
me in the rat. Values for propranolol do not appear to vary 
substantially between humans and animals (4, 15, 41, 46) with 
the exception of the monkey where the extraction ratio was 
found to be 0,49 (60). It would therefore seem that in the 
case of pindolol the extraction ratio is larger in the rat 
than in man. Metabolism in experimental animals is often 
greater than in humans (137). 
Hepatic Intrinsic Clearance 
79. 
The marked difference in extraction ratio between pro-
pranolol and pindolol was reflected by a very great difference 
in their respective hepatic intrinsic clearances (10,44 ml/g/min 
for propranolol; 3,42 ml/g/min for pindolol; p<0,001). Values 
of 10 ml/g/min (30) and 24 ml/min (uncorrected for liver weight) 
(17) have been reported for propranolol in the rat. 
Intrinsic hepatic clearance is a measure of the innate 
capacity of the liver to eliminate and metabolise a drug and 
it is independent of any limitations of blood flow. This in 
fact was confirmed in my experimental model where the corre-
lations between flow rates and intrinsic clearances of both 
propranolol (r = 0,23) and pindolol (r = 0,48) were non-signi-
ficant. 
Propranolol can thus be characterised as a high Cl. t in 
drug. Its Clint value always exceeds that of the liver blood 
flow (perfusate flow) and its extraction ratio is greater than 
0,7. Pindolol has an intermediate Cl. t (extraction ratio is in 
between 0,3 and 0,7) which is sometimes greater than, and at 
other times equal to, or less than, hepatic blood flow. It 
should be recalled that when blood flow is equal to Cl. t then Cl in 
extraction ratio is 0,50 (E = int ). A low Clint drug 
Q + Cl. t in 
has an extraction ratio that is less than 0,3. 
My results support the "venous-equilibration" model in 
that the extraction ratio calculated directly as AUCPV-AUCHV 
(equation 3) and 0 iv (equation 5) AUCPV 
Q.AUCPV 
agreed well with the extraction ratio calculated from the 
equation Clint derived from the "venous-equilibration'' 
Q + Cl. t in 
model. (See Tables 2a and b.) For example, in perfusion C 
of pindolol when Cl. twas equal to the perfusate flow, the in 
extraction ratio was 0,5 even when calculated according to 
equations 3 and 5. 
The AUCHV and Clint were independent of flow rate, as 
predicted by the model. 
so. 
Influence of flow Rate on Extraction Ratio and Hepatic Clearance 
According to the theoretical predictions of the "venous-
equilibration" model, high Cl. t (high extraction ratio) drugs in 
are classified as being flow-limited, i.e. their hepatic 
clearances are sensitive to changes in flow (page 13). Low 
Cl. t (low extraction ratio) drugs, on the other hand, are in 
capacity-limited, i.e. their hepatic clearances are sensitive 
not to flow but to the metabolic (enzymatic) capacity of the 
liver. Intermediate Clint (intermediate extraction ratio) 
drugs have hepatic clearances that are determined partly by 
flow and partly by hepatic metabolic function. 
In terms of the above classification, propranolol with 
its high Clint and high extraction ratio can be categorised 
as a flow-limited drug, while pindolol can be best regarded 
as a part flow-limited/part capacity-limited drug on account 
of its intermediate Cl. t and extraction ratio status. in 
Results obtained from my experiments confirm these pre-
dictions. Reference to Graph 18 shows the relationship be-
tween flow rate and extraction ratio. A plot of --f- against 
flow gave a straight line with an intercept of 1 and a slope 
1 
of Cl. as predicted by the "venous-equilibration" model. 
int 
This plot illustrates that increasing flow is accompanied by 
more marked changes in extraction ratio with pindolol (the 
slope of the line is greater) than with propranolol. This is 
also reflected in the highly significant negative correlation 
between flow and extraction ratio in the case of pindolol and 
the non-significant correlation in the propranolol group. 
Increasing liver blood flow therefore resulted in a de-
creasing extraction ratio but the decrease was proportionately 
much greater with pindolol than with propranolol. Hepatic 
clearance is the product of extraction ratio and blood flow. 
Thus with pindolol (an intermediate Cl. t' intermediate ex-in 
traction ratio), the increase in blood flow was paralleled 
by an appreciable decrease in extraction ratio, such that the 
product (i.e. hepatic clearance) was not predominantly affected 
by changes in flow (the latter being partly offset by opposite 
changes in extraction ratio). The situation with propranolol 
81. 
(a high Cl. t' high extraction ratio drug) was different. in 
Here increasing blood flow was accompanied by only a marginal 
decrease in extraction ratio; thus the product of the two 
variables {i . e. hepatic clearance) rose steeply. The hepatic 
clearance of propranolol was thus predominantly affected by 
changes in flow rate. 
My results clearly highlight these differences. An 
increase in flow of 71% resulted in a 49% increase in the 
hepatic clearance of propranolol whereas a similar increase 
in flow (67%) caused only a 15% increase in hepatic clearance 
of pindolol. As expected, the correlation between flow and 
hepatic clearance was larger for the propranolol perfusions 
(r = 0,97; p~0,001) than for pindolol (r = 0,87; p<0,05). The 
fact that a significant correlation emerged in the latter 
confirmed that pindolol was an intermediate Clint drug, i.e. 
one whose hepatic clearance was partly sensitive to flow. It 
is unlikely that a low Clint drug would have yielded a signi-
ficant correlation between flow and hepatic clearance. 
As propranolol has a higher extraction ratio than pindolol, 
one would expect that its hepatic clearance at any flow rate 
would be greater than that of pindolol. This was shown in my 
ex~eriments where the mean ClH of the propranolol perfusions 
(2,47 ml/g/min) was significantly greater than that for the 
pindolol perfusions (1,56 ml/g/min) (p<0,001). 
It might be argued that since flow is an important 
determinant of extraction ratio in the case of pindolol, the 
lower extraction ratio for pindolol in my study was an artefact. 
Although the mean flow rates between the pindolol and proprano-
lol groups did not differ significantly, the range of flow 
rates showed a slight variation. In order to exclude any dis-
torting effects of flow on extraction ratio t subgroups of per-
fusions were taken from the propranolol and pindolol groups, 
the flow rates in the subgroups being almost identically 
matched. A statistical analysis of these subgroups revealed 
no change in the significance of the findings previously de-
monstrated in the total groups. The mean extraction ratio 
for propranolol was still highly significantly greater than 
that for pindolol (p<0,01) (Table 2c). 
The same procedure was followed for the mean hepatic 
clearance: propranolol again yielded significantly higher 
values than pindolol (p~0,01) (Table 6). 
Compartment Models 
82. 
A notable difference in the pharmacokinetics of the 
drugs was the biphasic portal venous concentration-versus-
time curve for propranolol in comparison to the monophasic 
curve obtained in the case of pindolol. This indicated that 
propranolol obeyed a two-compartment open model whereas 
pindolol appeared to conform to a one-compartment model. 
The biphasic curve of propranolol represents: (a) a 
rapid ex. or distribution phase which primarily reflects the 
movement of drug from the central to the peripheral compart-
ment; and (b) a slowerJor elimination phase which is a 
hybrid of redistribution (peripheral to central compartment) 
and elimination. (See Fig. 3, page 5.) 
The apparent volume of distribution (Vd) is an index 
of the volume into which the drug appears to be distributed. 
Propranolol had a mean Vd of 21,23 ml/g of liver tissue 
(262 ml); this figure far exceeds the volume of the per-
fusate (103 ml). This indicated that the drug was extensively 
distributed beyond the central compartment. Pindolol, on the 
other hand, had a mean Vd of 8,72 ml/g of liver tissue (106 ml). 
This figure, being nearly equal to the volume of perfusate, 
suggested that pindolol was virtually confined to the intra-
vascular (central) compartment. 
I measured drug concentrations in total blood-KREBS per-
fusate: thus the central compartment included red blood cells 
and plasma. In my perfusion model the extravascular accumu-
lation of propranolol could only have occurred in the liver. 
Such an assumption, however, would not be tenable unless the 
binding of propranolol to glass or to other constituents of 
the apparatus had been discounted as a source of error. 
Particular care was taken to exclude such a possibility and 
this aspect is more fully discussed in an earlier section 
(page 52). 
Other workers have also observed a biphasic curve after 
rat liver perfusions with propranolol at doses of 5 mg and 
83. 
above (14, 101). However, they also found that at low doses 
drug concentrations declined monoexponentially. This indicated 
that the initial uptake of drug depended on a saturable process 
which at low doses resulted in complete extraction and at 
higher doses was responsible for theo<.-phase of the biexpon-
ential curve. Almost complete extraction of propranolol at 
low doses has been observed in man and dogs (4~ 46, 65). 
This initial rapid and avid uptake of propranolol has 
been shown to be due to physical binding of unchanged drug to 
liver tissue. Theo(.-phase was found to be independent of 
factors which inhibit metabolism such as temperature, oxygen 
and enzyme inhibitors, whereas the }-phase was sensitive to 
these factors (14, 101). When livers were perfused in the 
absence of oxygen, there was virtually no ~-phase although 
uptake in theo(-phase was not affected (101). Thus it would 
appear that the uptake and binding processes of propranolol 
(o<-phase) are qualitatively different from those involved in 
metabolism <i-phase). 
The binding of propranolol has been studied quantitatively 
in the rat. Homogenisation experiments have yielded estimates 
of over 170 : 1 for liver/perfusate drug concentrations at 
low concentrations whereas at higher concentrations (160pg/ml) 
this ratio decreased to 9,3: 1 (15). At concentrations of 
90 JA,9/ml unchanged propranolol was found in the liver in 
amounts 12 to 36 times higher than in the perfusate (101). 
Autoradiography has demonstrated that propranolol localises 
in the periportal zones and possibly also in certain cell 
types (101). 
It is hypothesised that propranolol binds to several 
sites each with different affinities within the liver. Equi-
librium dialysis and Scatchard plots have demonstrated high 
affinity-low capacity sites and low affinity-high capacity 
sites (101). The o(.-phase reflects binding to the high affinity 
site which, as previously mentioned, is saturable. Therefore, 
after saturation at higher doses, further binding takes place 
in the lower affinity-higher cap~city areas. 
Table 9 shows my calculations of the total amount of 
propranolol extracted from the perfusate at 5 minutes, i.e. 
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at the end of theo<.-phase. The average value was 329 pg/g of 
liver which may be regarded as an indication of the capacity 
of the so-called high affinity site. The only other such 
estimation in the literature was one of 500),Lg/g of liver (101). 
Distribution and Elimination Half-Life 
There was a very highly significant negative correlation 
between flow and thecx-phase half-life (tt>') of propranolol 
(p<0,01). This has also been shown by other workers (19, 101). 
The elimination half-life (t,~) of propranolol (5,1 minutes) 
was considerably longer than the t,~ (1 minute) but there was 
no correlation between t,~ and flow rate. Pindolol, on the 
other hand, showed a highly significant negative correlation 
between flow and t,! (p<0,01). Furthermore, the t 1j of pindo-
lol was shorter than that of propranolol. 
Table 10 shows the instantaneous extraction ratios for 
propranolol and pindolol at various times throughout the per-
fusion. Within theo{-phase of propranolol there was an ex-
ceedingly high extraction ratio, especially at 1 minute (0,99) 
and 3 minutes (0,94). During the ~-phase there was a marked 
decline in extraction ratio; in fact, the average extraction 
ratio of propranolol (0,39) in this phase was lower than the 
average extraction ratio for pindolol (0,52). 
It thus appears that propranolol is an exceptionally high 
extraction ratio drug in the oe.-phase because of the rapid 
(1 minute) and avid high affinity liver binding. Thereafter, 
in the i-phase it converts to a low extraction ratio drug, 
lower even than pindolol. 
This observation explains my finding of a high negative 
correlation between flow and t,cx.. Half-life is inversely re-
lated to hepatic clearance which, in the case of a very high 
extraction ratio drug (e.g. propranolol in theo<.-phase), is 
strongly determined by flow. Increasing flow rates would 
therefore lead to increasing hepatic clearances and to de-
creasing half-lives. 
In the ~-phase of propranolol, when the drug has con-
verted to a lower extraction ratio status, hepatic clearance 
is not so sensitive to flow but rather to metabolic factors. 
As I have demonstrated, there is no significant correlation 
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between flow and t,i· 
Pindolol has a fairly consistent extraction ratio 
throughout the perfusion (D,50 - D,60) and, as described 
earlier, falls into the intermediate category where hepatic 
clearance is partly sensitive to flow changes. It is thus 
not unexpected to obtain a negative correlation between flow 
and t, 1,· 
The t, i of pindolol is shorter than that of propranolol. 
No direct statistical analysis was done between the t!~ of 
propranolol and pindolol because the two drugs conformed to 
different compartmental models. In the case of the two-com-
partment, biexponential model the '13-phase is a composite of 
redistribution as well as elimination processes whereas the 
one-compartment, monoexponential system does not involve re-
distribution to any extent. 
The longer t,33of propranolol compared to pindolol may 
be explained in terms of both the redistribution and the 
elimination of prtipranolol. 
Previous work by Shand at al showed that, (when the liver 
was washed with drug-free perfusate) after perfusion with 
4 mg propranolol, 34% of propranolol was displaced from the 
rat liver into the perfusate (14). Since the dosage used in 
my experiments was even higher (5 mg), it was probable that 
there was appreciable redistribution of the drug back into 
the central compartment. The extent of this first-order re-
distribution would have accordingly prolonged the t!j• In 
the case of pindolol, such a redistribution effect (if any) 
is likely to have been negligible owing to its one-compartment 
disposition. 
Secondly, the longer half-life of propranolol might be 
accounted for by its reduced elimination in the $-phase. It 
has already been shown from the instantaneous extraction 
ratios that the extraction ratio of propranolol during the 
j-phase is lower than that of pindolol. However, this finding 
may also have arisen from redistribution - with higher effluent 
(hepatic vein) concentrations resulting in lower extraction 
ratios (E = AUCPV - AUCHV). 
AUCPV 
In the absence of quantitative data on the total amount 
of non-metabolised drug in the liver after the perfusion, it 
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is not possible to ascertain whether there are actual metabolic 
differences betwee n the two drugs. It must also be noted that 
elimination is an overall process which includes such processes 
as tissue binding and biliary excretion. 
The larger mean extraction ratio of propranolol (0,71) 
compared to pindolol (0,50) represents the first-pass effect. 
It is obvious that this overall greater first-pass effect is 
due to the very high extraction ratio values obtained for pro-
pranolol in theo<-phase and that these represent initial rapid 
and avid uptake and binding. The same reasoning would apply 
to the much higher hepatic intrinsic clearance derived for 
propranolol. It must be recalled that hepatic intrinsic 
clearance is an index not only of liver weight (I have corrected 
for this) and liver metabolism but . also of the partitioning of 
drug into the liver. This concept would explain the seemingly 
paradoxical situation where propranolol has a higher extraction 
ratio and a higher intrinsic clearance than pindolol and yet 
has a longer elimination half-life. It is, in fact, this 
specific property of physical binding to liver tissue that 
endows propranolol with its high clearance status. 
Hepatic uptake of the kind described for propranolol may 
be a feature of drugs with substantial first-pass effects, 
such as chlorpromazine, imipramine and nortriptyline. It is 
interesting that the latter drugs displace propranolol from 
rat liver binding sites (101) and that imipramine binds to 
rat tissue subcellular fractions. 
The location of liver binding sites is still unclear. 
Phenobarbitone can increase the capacity of the high affinity 
site in the rat liver, indicating that this site may be an 
inducible protein or lipoprotein (16). Propranolol is an 
amine with a pk of 9,45 so that most of its molecules, being 
a 
protonated cations at physiological pH, can bind to extra-
cellular and intracellular anions. 
The binding process may be dependent on the lipid solu-
bility of propranolol. Propranolol binds to mitochondrial 
membranes, microsomal sites and to the membrane constituents 
87. 
cardiolipin and phosphatidyl ethanolamine (101). 
It is interesting to note that propranolol and alpreno-
lol have the highest lipid solubilities within the ]-blocker 
class with octanol/wate; distribution ratios of 5,39 and 3,27 
respectively. These drugs also have the , highest first-pass 
extractions in man (70% and 90% respectively). Practolol has 
a very low lipid solubility (octanol/water 0,009) and it is 
virtually devoid of a first-pass effect. Pindolol has a low 
octanol/water distribution ratio (0,12) and a small first-
pass extraction (13%). 
It seems possible that the great difference in the lipid 
solubility (and perhaps tissue binding) between propranolol 
and pindolol may contribute substantially to the larger first-
pass effect of the former. 
This project has confirmed the validity of the rat liver 
perfusion model and has demonstrated its application in pre-
dicting the disposition of drugs. Although the results from 
an isolated in vitro rat model cannot necessarily be extra-
polated to man, the data derived therefrom may provide 
meaningful insights into the pharmacokinetics of a drug, 
particularly its first-pass extraction (bioavailability) and 
possible binding characteristics. 
The model has shown that hepatic intrinsic clearance is 
an important pharmacokinetic parameter. Its calculation is 
clinically simple, convenient and non-invasive. Furthermore, 
it can be derived clinically after administration of a single 
oral dose (from the formula 0o) and from this one can gain 
A"Oc 
o 
a reliable estimate of the first-pass effect ( = Clint ) 
Q + Clint 
and the bioavailability ( = l - E) of the drug (assuming a 
liver blood flow of 1,5 1/min and complete absorption). 
Hepatic intrinsic clearance provides an index of the drug's 
capacity to be eliminated by~ channels. It thus offers a 
useful basis by which to assess changes in drug clearance 
due to disease processes and/or interaction with other drugs. 
88. 
The perfusion-limited rat model as exemplified in this 
research might contribute usefully to a study of the pharmaco-
kinetics of a new drug in the preclinical phases as well as to 
comparative evaluations against existing compounds. 
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Graph 2i Fluorometric Deta~Jinafion of Pindolol. A plot or fluoreacanca 
lntanaity vareue concentration with each point in quadruplicat1. 
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Graph Sas Perfusion C \Propranolol). Semi-logarithmic plot or concen-
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Graph 6ci Perfusion D. (Propranolol). Hepatic vein concentration v1r1u1 
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Graph Baz Parrueion f (Propranolol). Semi-logarithmic plot or concen-
tration veraua time. flow rates 47 •1/min or 3,70 •1/v/min. 
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Graph 8b: Perfusion r (Propranolol). Portal vein concentration veraua 
time curve. Pointe were obtained troa the line titted in Graph Sa. 
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Gr a h lOa: Perfusion A (Pindolol). Semi~logarithmio plot of concan-
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Graph !ObJ Calculation or the area under the hepatic vein concentration 
versus time curve for parfuaion , A (Pindolol). Pointe were obtained from 
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Graph 15c: Perrueian f (Pindalal). Hepatic vein concentration ver1u1 t1•e 
curve. Point, were obtained fro• the line fitted in Graph 15a. 
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Graph 16c: Perfusion G (Pindolol). Hepat~a vein concentration vereue ti•• 
curve . Pointe were obtained from the line fitted in Graph 16a. 
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-Mean x = ~ N 
where N = sample number 
Standard Deviation SD 




Student's t test: 
t 
Degrees of freedom = 
(502)2 
N2 
(N 1 - 1) + (N 2 - 1) 
Correlation Co-efficient ~Product Momentl: 
~x 
2 Zx 2 ~ixl2 = - N 
ZY 2 = zv2 - ~z.Yl 2 N 
zxy = zxv - ~x 42.Y 
N 
r = 'Xl 
/~x2 z y 2 
t = r JN - 2 
/1 2 - r 
Degrees of freedom = N - 1 
. -
. ·- -~ -~ ,.- ~ 
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ALICHV = area under the hepatic vein drug concentration
 
versus time curve 
ALIC 
0 = 
area under the drug concentration versus time 
curve in the systemic circulation after oral 
administration 
ALICPV = area under the portal vein drug concentration 
versus time curve 
ALIC = area under s t
he drug concentration versus time 
curve in the systemic circulation after intra-
venous administration 
ClH = hepatic clearance of total drug 
Cl. t = in hepatic intrinsi
c clearance of total drug 
Cl. t ' = hepatic in intrinsic 
clearance of free drug 
C = drug 0 concentration
 at time zero 
D. = total intravenous dose l. V 
D = total oral dose 0 
E = hepatic extraction ratio 
f = bioavailability 
f = fraction of unbound drug in the blood 
Q = hepatic flow rate 
ti = elimination half-life 
vd = apparent volume of distribution 
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